

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent Advances in Understanding, Diagnosing, and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-84/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-84" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer" />
    
            <meta name="og:title" content="F1000Research Article: Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer.">
            <meta name="og:description" content="Read the latest article version by Kathryn Mills, Katherine Fuh, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="10752">
            <meta name="article-id" content="9977">
            <meta name="dc.title" content="Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer">
            <meta name="dc.description" content="Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal cancers, is the leading cause of gynecologic cancer mortality. To improve patient outcomes, the field is currently focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review summarizes recent advances in these areas.">
            <meta name="dc.subject" content="Ovarian cancer, cancer mechanisms, gene mutation, diagnosis and prevention">
            <meta name="dc.creator" content="Mills, Kathryn">
            <meta name="dc.creator" content="Fuh, Katherine">
            <meta name="dc.date" content="2017/01/27">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.9977.1">
            <meta name="dc.source" content="F1000Research 2017 6:84">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Ovarian cancer ">
            <meta name="prism.keyword" content=" cancer mechanisms ">
            <meta name="prism.keyword" content=" gene mutation ">
            <meta name="prism.keyword" content=" diagnosis and prevention">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/01/27">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="84">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.9977.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-84">
            <meta name="citation_title" content="Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer">
            <meta name="citation_abstract" content="Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal cancers, is the leading cause of gynecologic cancer mortality. To improve patient outcomes, the field is currently focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review summarizes recent advances in these areas.">
            <meta name="citation_description" content="Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal cancers, is the leading cause of gynecologic cancer mortality. To improve patient outcomes, the field is currently focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review summarizes recent advances in these areas.">
            <meta name="citation_keywords" content="Ovarian cancer, cancer mechanisms, gene mutation, diagnosis and prevention">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Kathryn Mills">
            <meta name="citation_author_institution" content="Washington University School of Medicine, St. Louis, MO, USA">
            <meta name="citation_author" content="Katherine Fuh">
            <meta name="citation_author_institution" content="Washington University School of Medicine, St. Louis, MO, USA">
            <meta name="citation_publication_date" content="2017/01/27">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="84">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.9977.1">
            <meta name="citation_firstpage" content="84">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-84/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-84.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=10752 /> <input type=hidden id=articleId name=articleId value=9977 /> <input type=hidden id=xmlUrl value="/articles/6-84/v1/xml"/> <input type=hidden id=xmlFileName value="-6-84-v1.xml"> <input type=hidden id=article_uuid value=ff0c7cca-6654-4c5f-9f28-37d70e478d29 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.9977.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.9977.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-84"
  },
  "headline": "Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer",
  "datePublished": "2017-01-27T16:30:28",
  "dateModified": "2017-01-27T16:30:28",
  "author": [
    {
      "@type": "Person",
      "name": "Kathryn Mills"
    },    {
      "@type": "Person",
      "name": "Katherine Fuh"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal cancers, is the leading cause of gynecologic cancer mortality. To improve patient outcomes, the field is currently focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review summarizes recent advances in these areas."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-84/v1",
            "name": "Recent Advances in Understanding, Diagnosing, and Treating Ovarian..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent Advances in Understanding, Diagnosing, and Treating Ovarian... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=10752 data-id=9977 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9977.1" data-recommended="" data-doi="10.12688/f1000research.9977.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-84/v1/pdf?article_uuid=ff0c7cca-6654-4c5f-9f28-37d70e478d29" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-9977-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-9977-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-9977-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Mills K and Fuh K. Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):84 (<a class=new-orange href="https://doi.org/10.12688/f1000research.9977.1" target=_blank>https://doi.org/10.12688/f1000research.9977.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-9977-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=9977 id=track-article-signin-9977 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9977?target=/articles/6-84/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10752 /> <input name=articleId type=hidden value=9977 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Kathryn Mills,&nbsp;</span><span class=""><a href="mailto:kfuh@wudosis.wustl.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Katherine Fuh</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Kathryn Mills,&nbsp;</span><span class=""><a href="mailto:kfuh@wudosis.wustl.edu" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Katherine Fuh</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 27 Jan 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.9977.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Washington University School of Medicine, St. Louis, MO, USA<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19780-19410></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=2272-19409></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19779-19408></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Ovarian cancer, a term that encompasses ovarian, fallopian, and peritoneal cancers, is the leading cause of gynecologic cancer mortality. To improve patient outcomes, the field is currently focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review summarizes recent advances in these areas. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Ovarian cancer, cancer mechanisms, gene mutation, diagnosis and prevention </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Katherine Fuh (<a href="mailto:kfuh@wudosis.wustl.edu">kfuh@wudosis.wustl.edu</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Katherine Fuh </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Mills K and Fuh K. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Mills K and Fuh K. Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):84 (<a href="https://doi.org/10.12688/f1000research.9977.1" target=_blank>https://doi.org/10.12688/f1000research.9977.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 27 Jan 2017, <b>6</b>(F1000 Faculty Rev):84 (<a href="https://doi.org/10.12688/f1000research.9977.1" target=_blank>https://doi.org/10.12688/f1000research.9977.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 27 Jan 2017, <b>6</b>(F1000 Faculty Rev):84 (<a href="https://doi.org/10.12688/f1000research.9977.1" target=_blank>https://doi.org/10.12688/f1000research.9977.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d62140e155>Introduction</h2><p class="" id=d62140e158>Ovarian cancer was first identified in 1959 by Dr Martin Swerdlow, who described a malignant pelvic mass that surrounded the left fallopian tube but did not involve the mucosal epithelium. This tumor was thought to develop from tissue with an origin similar to that of the ovary, such as the pelvic peritoneum, fallopian tubes, or uterus<sup><a href="#ref-1">1</a></sup>. Since then, cancers of these tissues have been collectively referred to as Müllerian adenocarcinomas to reflect the fact that we often do not know exactly which organ these tumors originate from. However, for simplicity, we will refer to these tumors by their more common name, ovarian cancers. Ovarian cancer is the most lethal gynecologic malignancy and is the fifth most common cause of cancer death in women<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>.</p><p class="" id=d62140e172>The majority of women with ovarian cancer are diagnosed with advanced-stage disease; only 15% of all cases are diagnosed with local disease<sup><a href="#ref-2">2</a>,<a href="#ref-3">3</a></sup>. Since the 1970s, the five-year survival for all stages has improved from 30% to 46%<sup><a href="#ref-3">3</a></sup> as a result of taxane and platinum chemotherapies, intraperitoneal (IP) administration of chemotherapy, and risk-reduction surgeries. However, five-year survival for advanced disease, such as stage IIIC, is a mere 39%. Risk factors for ovarian cancer include family history, nulliparity, lack of breast feeding, and infertility<sup><a href="#ref-4">4</a></sup>. In addition, between 5% and 15% of all women with ovarian cancer have inherited mutations in DNA repair genes such as <i>BRCA1</i>, <i>BRCA2</i>, and genes associated with Lynch syndrome<sup><a href="#ref-4">4</a>–<a href="#ref-7">7</a></sup>. <i>BRCA1</i>, <i>BRCA2</i>, and Lynch mutations increase the lifetime risks of ovarian cancer by as much as 60-, 30-, and 13-fold, respectively<sup><a href="#ref-5">5</a>,<a href="#ref-8">8</a></sup>. Currently, the field is focused on defining the mechanisms of cancer formation and spread, early diagnosis and prevention, and developing novel therapeutic options. This review highlights some of the newest findings in these areas.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d62140e220>Mechanisms of ovarian cancer formation and spread</h2><div class=section><a name=d62140e223 class=n-a></a><h3 class=section-title>Tumor types</h3><p class="" id=d62140e228>The majority of ovarian cancers are of epithelial histology, and high-grade serous carcinomas (HGSCs) are the most common, but there are other epithelial histologic subtypes, such as clear cell, endometrioid, and mucinous<sup><a href="#ref-4">4</a></sup>. These can be divided into two major subtypes: type I and type II. Type I cancers (clear cell, endometrioid, and low-grade serous) grow slowly and seem to develop in a step-wise process. For example, low-grade serous tumors arise from benign serous cystadenoma or Müllerian inclusion cysts that accumulate mutations in pathways such as KRAS and BRAF<sup><a href="#ref-9">9</a></sup>. Likewise, clear cell and endometrioid carcinomas may originate from endometriosis as shown by the finding that the prevalence of self-reported endometriosis was higher in women with clear cell (20%) and endometrioid (14%) cancers than in those with low-grade serous (9.2%) or mucinous (6%) cancers<sup><a href="#ref-10">10</a></sup>. Type II tumors are characterized by high-grade, rapidly progressive disease, and most commonly a serous histology<sup><a href="#ref-11">11</a>,<a href="#ref-12">12</a></sup>.</p></div><div class=section><a name=d62140e251 class=n-a></a><h3 class=section-title>Origin of disease</h3><p class="" id=d62140e256>Although ovarian cancers were traditionally thought to originate from the surface epithelium of the ovary, there is strong evidence that a portion (50–60%) of high-grade serous ovarian tumors arise from the fallopian tube, and many pathologists have described pre-invasive dysplastic lesions within the distal end of the fallopian tube. These serous tubal intraepithelial carcinoma (STIC) lesions<sup><a href="#ref-11">11</a>,<a href="#ref-13">13</a>–<a href="#ref-16">16</a></sup> often resemble high-grade serous cancer, confirming that ovarian serous cancer can originate in the fallopian tube. However, two recent studies indicate that STIC lesions sometimes represent a metastatic site rather than assumptive primary fallopian tube cancers<sup><a href="#ref-17">17</a>,<a href="#ref-18">18</a></sup>. In one study, Eckert <i>et al</i>. implanted HGSC spheroids into the fallopian tube epithelium in mice and showed that this fallopian tube growth histologically mimicked STIC lesions<sup><a href="#ref-17">17</a></sup>. In another study, McDaniel <i>et al</i>. performed targeted next-generation sequencing of an incidental STIC lesion and found that it matched the associated uterine endometrioid carcinoma, strongly indicating that the STIC lesion originated as a micrometastasis from the primary tumor<sup><a href="#ref-18">18</a></sup>. Thus, although certain aspects regarding the origins of high-grade serous ovarian cancer are understood, unanswered questions continue to challenge the field.</p></div><div class=section><a name=d62140e292 class=n-a></a><h3 class=section-title>Mutations and pathways</h3><p class="" id=d62140e297>The Cancer Genome Atlas study characterized 316 primary HGSC specimens and detected <i>TP53</i> mutations in 100% of specimens and <i>BRCA1</i> and <i>BRCA2</i> mutations (both somatic and germline) in 20%<sup><a href="#ref-19">19</a>,<a href="#ref-20">20</a></sup>. Most tumors were characterized by global genomic instability. More recent advances in DNA sequencing technology have identified additional mutations in ovarian cancer, including <i>BARD1</i>, <i>BRIP1</i>, <i>CHEK2</i>, <i>NBN</i>, <i>PALB2</i>, <i>RAD50</i> family, and <i>NF1</i><sup><a href="#ref-12">12</a>,<a href="#ref-21">21</a>–<a href="#ref-26">26</a></sup>. Given that these genes are involved in DNA repair, women with ovarian cancer, as well as their family members, are at risk of developing other cancers and thus should be referred for genetic counseling and testing<sup><a href="#ref-27">27</a></sup>.</p><p class="" id=d62140e352>In ovarian cancer, as in other cancers, resistance to chemotherapy is common. To identify genes conferring chemoresistance, Patch <i>et al</i>. analyzed whole genome sequences of 92 patients with HGSC to characterize mutations from three groups of tumors: those that were sensitive to platinum, those that initially responded but then developed resistance, and those that did not respond at all<sup><a href="#ref-28">28</a></sup>. They found <i>TP53</i> mutations in all samples but found only a few, low-frequency, actionable genetic alterations amongst the chemoresistant patients. These included reversion of germline mutations in <i>BRCA1</i> and <i>BRCA2</i>, mutations in the pro-apoptotic genes <i>FOXO1</i> and <i>BCL2L11</i>, and increased expression of <i>ABCB1</i>, which encodes a cellular drug efflux pump. More work is clearly needed to uncover mechanisms of chemoresistance and strategies to overcome it.</p></div><div class=section><a name=d62140e382 class=n-a></a><h3 class=section-title>Mechanisms of metastasis</h3><p class="" id=d62140e387>Ovarian cancers are extremely prone to metastasize, particularly to the omentum. Two routes have been proposed to explain how ovarian cancer cells reach the omentum. First, they may travel through the bloodstream, as suggested by Sood <i>et al</i>.<sup><a href="#ref-29">29</a></sup>. These authors vascularly conjoined 15 pairs of mice, intraperitoneally injected tumor cells into “host” mice, and found that half of the conjoined “guest” mice developed omental or mesenteric metastases. Tumor cells also reached the guest mouse when the cancer cells were injected into host ovaries or vasculature. The authors further found that the metastatic cells significantly upregulated expression of epidermal growth factor receptor family genes, specifically <i>ErbB3</i>, and that targeting <i>ErbB3</i> with small interfering RNA significantly inhibited omental tumor establishment and also the size and number of tumors<sup><a href="#ref-29">29</a></sup>. A second theory is that ovarian cancer cells metastasize by shedding into the peritoneal space and then attaching to nearby structures, such as the omentum. Support for this model comes from Lengyel <i>et al</i>., who showed that omental adipocytes promote metastasis to the omentum by upregulating expression of fatty acid-binding protein 4 (<i>FABP4</i>)<sup><a href="#ref-30">30</a></sup>. <i>FABP4</i> was strongly expressed at the adipocyte–cancer cell interface, and mice lacking <i>FABP4</i> had a significantly lower tumor burden than wild-type mice. Future work will hopefully reveal whether the hematogenous or the shedding route predominates in different ovarian cancer types so that therapies can be developed to prevent it.</p></div><div class=section><a name=d62140e426 class=n-a></a><h3 class=section-title>Tumor cells and the microenvironment</h3><p class="" id=d62140e431>Mutations do not explain the full spectrum of tumor behaviors, which also depend on the tumor microenvironment, or stroma, a mixture of extracellular matrix, mesothelial cells, fibroblasts, endothelial cells, blood and lymph vessels, nerves, immune cells, and adipocytes<sup><a href="#ref-31">31</a>–<a href="#ref-33">33</a></sup>. Two hallmarks of cancer that depend on the tumor microenvironment are (1) stromal invasion and metastasis and (2) angiogenesis. Because stromal components contribute to ovarian cancer metastasis, many investigators are developing <i>in vitro</i> methods to study interactions with the tumor cells and identify strategies to inhibit metastasis by targeting tumor/microenvironment interactions. These methods include three-dimensional matrices, cancer cell spheroids, and co-cultured mesothelium (the first layer of the omentum) with cancer cells<sup><a href="#ref-34">34</a></sup>. In studies with spheroids, Davidowitz <i>et al</i>. found that tumor cell spheroids that upregulated their expression of epithelial-to-mesenchymal transition transcription factors (in particular, SNAI1, TWIST1, and ZEB1) were better able to clear the mesothelium (an essential step in metastasis) than cells that did not upregulate these factors<sup><a href="#ref-35">35</a></sup>. Additionally, receptor tyrosine kinases such as AXL and DDR2 have been found to regulate tumor cell clearance of primary, patient-derived mesothelial cells<sup><a href="#ref-36">36</a>,<a href="#ref-37">37</a></sup>. For angiogenesis, Sood <i>et al</i>. used a xenograft approach to model what happens when a patient stops taking an anti-angiogenic drug such as bevacizumab or pazopanib<sup><a href="#ref-38">38</a></sup>. They found that mice with higher circulating platelet levels had greater tumor weight and markers of proliferation and decreased levels of apoptosis. Furthermore, this group demonstrated that tumor infiltration of platelets after withdrawal of anti-angiogenic agents may contribute to rebound tumor growth. Incorporating the tumor microenvironment in future work will continue to lead to a better understanding of ovarian carcinogenesis and metastasis.</p></div><div class=section><a name=d62140e471 class=n-a></a><h3 class=section-title>Translational mouse models</h3><p class="" id=d62140e476>Understanding disease pathogenesis necessitates models that mimic patient tumor behavior and interaction with the microenvironment. One approach is to develop genetically engineered mouse models (GEMMs), in which a mouse’s genome is modified to cause development of a murine disease that mimics human disease, although such models have not clearly resolved the question about the origin of ovarian tumors. Some authors have created conditional GEMMs that point to the ovary as the origin<sup><a href="#ref-39">39</a>–<a href="#ref-42">42</a></sup>, whereas other evidence points to the fallopian tube<sup><a href="#ref-43">43</a>,<a href="#ref-44">44</a></sup>. The first ovarian cancer model based on transformation of the fallopian tube epithelium as the origin was derived by using the Müllerian-specific <i>Ovgp1</i> promoter to drive expression of the SV40 large T-antigen and thus induce tumorigenesis in the fallopian tube<sup><a href="#ref-45">45</a></sup>. More recently, Perets <i>et al</i>. generated a model in which they specifically deleted <i>BRCA</i>, <i>TP53</i>, or <i>PTEN</i> in the fallopian tube and found that these mice developed HGSCs, tubal transformation, and peritoneal spread<sup><a href="#ref-46">46</a></sup>. Interestingly, when the researchers removed the ovaries, the mice developed STIC lesions and tubal transformation but not peritoneal metastasis, suggesting that the ovary plays a crucial role in the spread of IP disease<sup><a href="#ref-46">46</a></sup>.</p><p class="" id=d62140e521>A second type of <i>in vivo</i> model is cell line-based xenografts, in which cancer cell lines are implanted into an immunocompromised mouse or, even better, into a mouse that is syngeneic with the cell line, such as the spontaneous ovarian cancer line ID8 derived from a C57Bl/6 mouse. Although this ID8 line has been used for many years, Walton <i>et al</i>. recently sequenced it and found that it was wild-type for <i>TP53</i> and <i>BRCA1</i> and <i>BRCA2</i><sup><a href="#ref-47">47</a></sup>, whereas 98% of human ovarian cancers contain a <i>TP53</i> mutation. Introducing a <i>TP53</i> or <i>BRCA2</i> mutation (or both) caused these cells to develop tumors and surrounding microenvironment phenotype that more closely mimicked human ovarian cancers in terms of speed and distribution of metastases.</p><p class="" id=d62140e552>A third approach to translational mouse models is the use of patient-derived xenografts (PDXs), which are created by implanting patient specimens into mice to study tumor behaviors. Several groups have developed ovarian cancer PDXs<sup><a href="#ref-48">48</a>–<a href="#ref-51">51</a></sup> that respond to treatment in a manner similar to that of the patients’ tumors. For example, Landen <i>et al</i>. created subcutaneous PDX models of ovarian cancer and assessed gene expression in both the patients’ tumors and the PDXs after they developed chemoresistance<sup><a href="#ref-50">50</a></sup>. The authors identified five affected signaling pathways (protein kinase A, GNRH, sphingosine-1-phosphate, α-adrenergic, and cholecystokinin/gastrin-mediated) that were shared between the patients’ tumors and the corresponding PDXs. Models such as these provide usable platforms to study tumor and stromal elements contributing to tumorigenesis and the effects of various therapies.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d62140e573>Diagnosis and prevention</h2><div class=section><a name=d62140e576 class=n-a></a><h3 class=section-title>Screening in low-risk patients</h3><p class="" id=d62140e581>No validated screening tests exist for early detection of ovarian cancer in low-risk women. Although some tests have been developed to assess known adnexal masses, the US Food and Drug Administration (FDA) recently issued a statement recommending against using any of these as screening tools in the general population<sup><a href="#ref-52">52</a></sup>. Similarly, the US Preventative Services Task Force gives screening asymptomatic women a D grade, meaning that there is moderate to high certainty that the service has no net benefit or that the harms of such a service may outweigh any benefit<sup><a href="#ref-53">53</a></sup>. For example, the FDA has approved the OVA1 test for women who have already been found to have an ovarian tumor, but it is not a screening test. The largest randomized controlled trials (RCTs) have assessed a combination of serum markers and ultrasound imaging, but these tests have proved to have inadequate sensitivity or specificity, have resulted in high rates of unnecessary interventions (65–97% of screen-positive women who underwent surgical intervention did not actually have cancer), or were unable to reduce ovarian cancer-related mortality<sup><a href="#ref-54">54</a>–<a href="#ref-56">56</a></sup>. This is an important area for future research.</p></div><div class=section><a name=d62140e600 class=n-a></a><h3 class=section-title>Special considerations in high-risk patients</h3><p class="" id=d62140e605>Patients who carry particular inherited mutations warrant screening<sup><a href="#ref-57">57</a></sup> because the lifetime risk of ovarian cancer in the general populations is 1.3% but can be as high as 40–60% in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers<sup><a href="#ref-58">58</a>–<a href="#ref-62">62</a></sup> and 10–15% in Lynch syndrome mutation carriers<sup><a href="#ref-5">5</a>,<a href="#ref-63">63</a></sup>. As additional high-risk mutations are identified in multi-gene panels, we may be able to identify more high-risk patients.</p></div><div class=section><a name=d62140e633 class=n-a></a><h3 class=section-title>Advances in high-risk prevention</h3><p class="" id=d62140e638>Women who carry high-risk mutations are recommended to undergo risk-reducing bilateral salpingo-oophorectomy (RRSO) (removal of the fallopian tubes and ovaries) by age 35 to 40 for <i>BRCA1</i> and 40 to 45 for <i>BRCA2</i><sup><a href="#ref-27">27</a>,<a href="#ref-64">64</a></sup>. A national trial (GOG-0199) comparing RRSO with longitudinal screening will hopefully clarify both the necessary screening frequency and the non-oncological outcomes of ovary removal, such as heart disease and osteoporosis<sup><a href="#ref-65">65</a></sup>, in high-risk patients.</p><p class="" id=d62140e657>Because removal of the ovary can cause earlier onset of menopause, increased risks to cardiac and bone health, and other impairments to quality of life, studies are underway to determine the efficacy of removing the fallopian tubes (salpingectomy) immediately but delaying ovary removal (oophorectomy) for several years. Harmsen <i>et al</i>. used previous data of cumulative ovarian cancer risk for BRCA mutation carriers to mathematically compare the risks of immediate RRSO with those of immediate salpingectomy with delayed oophorectomy<sup><a href="#ref-66">66</a></sup>. The authors concluded that a five-year delay in oophorectomy would increase the rates of ovarian cancer by 4.1% and 1.8% for those with mutations in <i>BRCA1</i> and <i>BRCA2</i>, respectively, even if the initial salpingectomy afforded no reduction of risk. Kwon <i>et al</i>. created a model to compare costs and benefits of RRSO at age 40 versus salpingectomy at age 40 with oophorectomy at age 50 in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers<sup><a href="#ref-67">67</a></sup>. Although RRSO at age 40 was more effective in both cost and overall life expectancy, salpingectomy plus delayed oophorectomy resulted in higher quality-adjusted life expectancy.</p></div><div class=section><a name=d62140e688 class=n-a></a><h3 class=section-title>Hormonal agents in high-risk patients</h3><p class="" id=d62140e693>An important issue to consider is that RRSO is associated with menopausal symptoms such as sexual dysfunction, hypoactive sexual desire, and less frequent sexual encounters<sup><a href="#ref-68">68</a>–<a href="#ref-70">70</a></sup>. Thus, RRSO patients may receive hormone therapy, which Kwon <i>et al</i>. assumed would not be the case in the cost–benefit analysis discussed above. Thus far, no RCTs have been conducted to address this issue. One recent systematic literature review<sup><a href="#ref-71">71</a></sup> assessed the safety of hormone therapy in RRSO patients with BRCA mutations and found that women were likely to benefit symptomatically from hormone therapy and did not have an increased risk of breast cancer, but there was insufficient evidence regarding ovarian cancer risk. Additional studies are needed to assess ovarian cancer risk and outcomes of risk-reducing procedures in patients carrying Lynch syndrome mutations.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d62140e714>Optimizing chemotherapy and developing innovative therapeutics</h2><div class=section><a name=d62140e717 class=n-a></a><h3 class=section-title>Optimizing chemotherapy</h3><p class="" id=d62140e722>Chemotherapy has long been incorporated into the care of patients with HGSC; however, the how, when, and which have become less clear as more options are available for front-line treatment. In the first decade of the 21st century, two randomized trials (GOG 114 and GOG 172) demonstrated that, after optimal tumor resection, women who received combination intravenous/IP (IV/IP) cisplatin and paclitaxel-containing chemotherapy had significantly better progression-free survival (PFS) (5.7 and 5.5 months) and overall survival (OS) (11.0 and 15.9 months) than those who received IV-only regimens<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. This survival advantage in the IP groups was seen even though the IP patients had significant hematologic, metabolic, neurologic, and gastrointestinal toxicities, and only 71% and 42% of each study’s IP participants completed all six cycles<sup><a href="#ref-72">72</a>,<a href="#ref-73">73</a></sup>. Because of these toxicities and missed cycles, over time providers modified the regimen and instead gave patients alternate therapy schedules, reduced dosages, and substituted drugs, as described by Wright <i>et al</i>.<sup><a href="#ref-74">74</a></sup>. Another option for chemotherapy regimen was provided by a Japanese study showing that a lower but more frequent dose of paclitaxel (“dose-dense paclitaxel”) led to improved PFS and OS<sup><a href="#ref-75">75</a></sup>. Additionally, the GOG-0218 trial demonstrated that the use of bevacizumab in the front-line and maintenance setting improved PFS by 3.8 months when compared with conventional every-3-weeks carboplatin and paclitaxel<sup><a href="#ref-76">76</a></sup>.</p><p class="" id=d62140e755>Recently, the GOG-0252 trial was undertaken in an attempt to identify the best front-line regimen given the improved survival data seen with IP chemotherapy and dose-dense paclitaxel when compared with conventional every-3-weeks carboplatin and paclitaxel. This study had three arms, each of which included bevacizumab therapy in addition to (1) IV dose-dense paclitaxel and IV carboplatin, (2) IV dose-dense paclitaxel and IP carboplatin, and (3) IV/IP paclitaxel with IP cisplatin at a reduced dose. PFS and toxicities were found to be similar amongst all three treatment regimens, although some participant cross-over between arms may have clouded results<sup><a href="#ref-77">77</a></sup>. We are awaiting OS data as they mature to help determine whether there is a superior front-line regimen.</p><p class="" id=d62140e762>Not only has the best route been intensely debated but the optimal timing of therapy has been and is currently being studied. Chemotherapy is usually given either (1) only after primary debulking surgery (PDS) or (2) as both neoadjuvant chemotherapy (NACT) before and after interval debulking surgery (IDS). The goal of any cytoreductive surgery is to maximally reduce the disease, as doing so is well known to improve patient outcomes<sup><a href="#ref-78">78</a>–<a href="#ref-80">80</a></sup>. However, recent trials have tried to determine whether patients receiving NACT and post-IDS chemotherapy have better outcomes than those receiving only chemotherapy after PDS. Initially, several large RCTs found that the NACT/IDS regimen was non-inferior to the PDS regimen in terms of PFS and OS and overall morbidities. However, the OS of the groups was lower than expected, suggesting that the included patients somehow differed from the larger collective population of patients with HGSC<sup><a href="#ref-81">81</a>–<a href="#ref-84">84</a></sup>. Subsequent reports noted that recurrences after NACT/IDS regimens were more likely to be platinum-resistant and were less responsive to second-line therapies than those that occurred after PDS regimens, and some studies even demonstrated better PFS and OS in those who received regimens after PDS<sup><a href="#ref-85">85</a>–<a href="#ref-90">90</a></sup> when compared with those after NACT/IDS. There is likely a contributing biological factor, yet to be determined, for tumors that present as unresectable versus those that can be resected to no residual disease with PDS. Controversy with NACT/IDS exists given the possibility of a compromised responsiveness to additional lines of therapy including platinum-containing agents and possibly a risk of higher recurrence rates. Nonetheless, a NACT/IDS regimen may be the best option for patients with particular comorbidities, histological subtypes, or other clinical situations making them unable to tolerate an aggressive, up-front surgical procedure.</p></div><div class=section><a name=d62140e787 class=n-a></a><h3 class=section-title>Developing innovative therapeutics</h3><p class="" id=d62140e792>Traditionally, ovarian cancer has been treated with cytotoxic agent regimens chosen on the basis of cancer stage, and most patients have eventually developed chemotherapy resistance, leading to overwhelming disease burden and death. Researchers are working to find innovative methods to restore chemosensitivity and develop adjuvants to improve the function of cytotoxics to decrease required doses and improve toxicity profiles. In addition, researchers are investigating novel agents targeting specific tumor mutations. We highlight some promising findings below.</p></div><div class=section><a name=d62140e796 class=n-a></a><h3 class=section-title>Preclinical development</h3><p class="" id=d62140e801>Nanoparticle technology is a promising method by which to introduce therapeutics and minimize off-target effects. In one study, Landen <i>et al</i>. treated a mouse model of ovarian cancer with nanoliposomal particles containing small interfering RNAs targeting cancer stem cells in combination with either docetaxel or cisplatin<sup><a href="#ref-91">91</a></sup>. This regimen reduced tumor growth more than chemotherapy alone. In another study, researchers used nanoliposomal particles to target a cell membrane transporter involved in cellular extrusion of chemotherapeutic drugs. This approach was able to restore paclitaxel sensitivity both <i>in vitro</i> and <i>in vivo</i><sup><a href="#ref-92">92</a></sup>. A nanoparticle derived of a naturally occurring alcohol was recently demonstrated to improve apoptosis and inhibit tumor growth when combined with paclitaxel <i>in vitro</i> and <i>in vivo</i><sup><a href="#ref-93">93</a></sup>. Other promising therapeutics target various parts of the surrounding tumor stroma. For example, Wang <i>et al</i>. found that the peptide prosaposin could inhibit metastasis in a platinum-resistant PDX model by stimulating the release of anti-tumorigenic protein thrombospondin-1 from surrounding monocytes<sup><a href="#ref-94">94</a></sup>.</p></div><div class=section><a name=d62140e838 class=n-a></a><h3 class=section-title>SHIVA and MATCH clinical trials</h3><p class="" id=d62140e843>Given the success of targeted therapies based on tumor mutational status in lung cancer and melanoma, this approach is being investigated in other solid cancers, including ovarian cancer. The SHIVA (A Randomized Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer) trial in France was a multicenter, phase II RCT of 195 histology-agnostic, heavily pretreated patients (of whom 29 had ovarian cancer). Patients were randomly assigned to either the physician’s choice of drug or a molecularly targeted agent that was matched to the patient tumor molecular profile but was not approved for that tumor type. Although the study reported no difference in PFS between the two groups<sup><a href="#ref-95">95</a></sup>, the study was powered to detect only a 15–30% improvement and may have missed smaller effects. In the ongoing National Cancer Institute-initiated Molecular Analysis for Therapy Choice (MATCH) trial, all recurrent, solid tumors undergo targeted exome sequencing to identify mutations, and the patients are treated with a matched targeted therapy until disease progression<sup><a href="#ref-96">96</a></sup>. This ongoing trial includes patients with ovarian cancer and will provide useful information about the value of this genomics-based approach to treatment.</p></div><div class=section><a name=d62140e856 class=n-a></a><h3 class=section-title>FDA-approved agents</h3><p class="" id=d62140e861>Only two targeted agents are currently FDA-approved for use in ovarian cancer. Olaparib, a poly-ribose polymerase (PARP) inhibitor, was approved in 2014 for use in patients with <i>BRCA1/2</i> mutations who have been treated with three or more previous lines of chemotherapy. Bevacizumab, a vascular endothelial growth factor (VEGF) anti-angiogenic, also received FDA approval in 2014 for use in recurrent, platinum-resistant patients in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin. A number of other targeted therapeutics, including additional PARP inhibitors, anti-angiogenics, tyrosine kinase inhibitors, and immunotherapeutics, are currently being investigated (<a href="#T1">Table 1</a>).</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Recent and ongoing clinical trials using targeted therapeutics for high-grade serous Müllerian adenocarcinomas.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d62140e881 class=n-a></a><thead><a name=d62140e883 class=n-a></a><tr><a name=d62140e885 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d62140e887 class=n-a></a>Class</th><th align=left colspan=1 rowspan=1 valign=top><a name=d62140e890 class=n-a></a>Agent</th><th align=left colspan=1 rowspan=1 valign=top><a name=d62140e893 class=n-a></a>Target(s)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d62140e896 class=n-a></a>Trial group/name, phase</th><th align=left colspan=1 rowspan=1 valign=top><a name=d62140e899 class=n-a></a>Progression-free<br class=br>survival and overall<br class=br>survival, months</th></tr></thead><tbody><a name=d62140e908 class=n-a></a><tr><a name=d62140e910 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e912 class=n-a></a>Anti-angiogenics</td><td colspan=1 rowspan=1><a name=d62140e915 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e917 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e919 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e921 class=n-a></a></td></tr><tr><a name=d62140e924 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e926 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e928 class=n-a></a>Bevacizumab<sup><a href="#fn1">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e934 class=n-a></a>VEGF</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e937 class=n-a></a>ICON-7, phase III<sup><a href="#ref-101">101</a></sup><br class=br>GOG-0218, phase III<sup><a href="#ref-76">76</a></sup><br class=br><br class=br>OCEANS, phase III<sup><a href="#ref-102">102</a></sup><br class=br>AURELIAa, phase III<sup><a href="#ref-103">103</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e960 class=n-a></a>PFS 19.8/OS 36.6<br class=br>PFS 11.2+14.1/OS<br class=br>38.7+39.7<br class=br><br class=br>PFS 12.4/OS 33.3<br class=br>PFS 6.7/OS 16.6</td></tr><tr><a name=d62140e973 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e975 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e977 class=n-a></a>Cabozantinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e980 class=n-a></a>c-met, VEGFR2, RET,<br class=br>AXL</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e985 class=n-a></a> <i>NRG-GY001, phase II</i><sup><a href="#ref-104">104</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e993 class=n-a></a>-</td></tr><tr><a name=d62140e997 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e999 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1001 class=n-a></a>Cediranib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1004 class=n-a></a>VEGFR2/3/4, c-kit </td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1007 class=n-a></a>Multicenter, phase II<sup><a href="#ref-105">105</a></sup><br class=br> <i>NRG-GY004, phase III</i><sup><a href="#ref-106">106</a></sup><br class=br> <i>NRG-GY005, phase II/III</i><sup><a href="#ref-107">107</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1027 class=n-a></a>PFS 5.2/OS 16.3<br class=br>-<br class=br>-</td></tr><tr><a name=d62140e1035 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1037 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1039 class=n-a></a>Fosbretabulin</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1042 class=n-a></a>Endothelial<br class=br>microtubules</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1047 class=n-a></a>GOG-0186I, phase II<sup><a href="#ref-108">108</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1053 class=n-a></a>PFS 7.3/OS 24.6</td></tr><tr><a name=d62140e1058 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1060 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1062 class=n-a></a>Trebananib/AMG386</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1065 class=n-a></a>Angiopoietin-1/2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1068 class=n-a></a>TRINOVA1, phase III<sup><a href="#ref-109">109</a>,<a href="#ref-110">110</a></sup><br class=br><i>TRINOVA2-3, phase III</i><sup><a href="#ref-111">111</a>,<a href="#ref-112">112</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1086 class=n-a></a>PFS 7.2/OS 19.3<br class=br>-</td></tr><tr><a name=d62140e1092 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1094 class=n-a></a>PARP inhibitors</td><td colspan=1 rowspan=1><a name=d62140e1097 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1099 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1101 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1103 class=n-a></a></td></tr><tr><a name=d62140e1106 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1108 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1110 class=n-a></a>Olaparib<sup><a href="#fn1">a</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1116 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1119 class=n-a></a>Multicenter<sup><a href="#fn1">a</a></sup>, phase II<sup><a href="#ref-113">113</a></sup><br class=br>Multicenter, phase II<sup><a href="#ref-114">114</a>,<a href="#ref-115">115</a></sup><br class=br><i>NRG-GY004, phase III</i><sup><a href="#ref-106">106</a></sup><br class=br><i>NRG-GY005, phase II/III</i><sup><a href="#ref-107">107</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1150 class=n-a></a>PFS 7.0/OS 16.6<br class=br>PFS 8.4/OS 29.8<sup><a href="#fn1">b</a></sup><br class=br><br class=br>-<br class=br>-</td></tr><tr><a name=d62140e1164 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1166 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1168 class=n-a></a>Niraparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1171 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1174 class=n-a></a>ENGOT-OV16/Nova Trial<br class=br>(multi-arm), phase III<sup><a href="#ref-116">116</a></sup><br class=br><i>QUADRA, phase II</i><sup><a href="#ref-117">117</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1188 class=n-a></a>PFS 21+12.9+9.3 /OS<br class=br>not yet mature<br class=br><br class=br>-</td></tr><tr><a name=d62140e1197 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1199 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1201 class=n-a></a>Veliparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1204 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1207 class=n-a></a> <i>GOG-3005, phase III</i><sup><a href="#ref-118">118</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1215 class=n-a></a>-</td></tr><tr><a name=d62140e1219 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1221 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1223 class=n-a></a>Rucaparib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1226 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1229 class=n-a></a> <i>ARIEL2-4, phase II/III</i><sup><a href="#ref-119">119</a>–<a href="#ref-121">121</a></sup> </td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1241 class=n-a></a>-</td></tr><tr><a name=d62140e1246 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1248 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1250 class=n-a></a>Pazopanib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1253 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1256 class=n-a></a> <i>GOG-0186J, phase II</i><sup><a href="#ref-122">122</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1264 class=n-a></a>-</td></tr><tr><a name=d62140e1268 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1270 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1272 class=n-a></a>Cabozantinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1275 class=n-a></a>PARP</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1278 class=n-a></a> <i>GOG-0186K, phase II</i><sup><a href="#ref-123">123</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1286 class=n-a></a>-</td></tr><tr><a name=d62140e1290 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1292 class=n-a></a>Immunologics</td><td colspan=1 rowspan=1><a name=d62140e1295 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1297 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1299 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1301 class=n-a></a></td></tr><tr><a name=d62140e1304 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1306 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1308 class=n-a></a>EGEN-001</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1311 class=n-a></a>IL-12</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1314 class=n-a></a>GOG-0170Q, phase II<sup><a href="#ref-124">124</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1320 class=n-a></a>PFS 2.9/OS 9.2</td></tr><tr><a name=d62140e1324 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1326 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1328 class=n-a></a>Nivolumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1331 class=n-a></a>PD-1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1334 class=n-a></a> <i>NRG-GY003, phase II</i><sup><a href="#ref-125">125</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1342 class=n-a></a>-</td></tr><tr><a name=d62140e1346 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1348 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1350 class=n-a></a>Ruxolitinib</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1353 class=n-a></a>JAK1, JAK2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1356 class=n-a></a> <i>NRG-GY007, phase I/II</i><sup><a href="#ref-126">126</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1364 class=n-a></a>-</td></tr><tr><a name=d62140e1369 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1371 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1373 class=n-a></a>VTX-2337</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1376 class=n-a></a>TLR8</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1379 class=n-a></a> <i>GOG-3003, phase II</i><sup><a href="#ref-127">127</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1387 class=n-a></a>-</td></tr><tr><a name=d62140e1391 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1393 class=n-a></a>Pathway inhibitors</td><td colspan=1 rowspan=1><a name=d62140e1396 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1398 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1400 class=n-a></a></td><td colspan=1 rowspan=1><a name=d62140e1402 class=n-a></a></td></tr><tr><a name=d62140e1405 class=n-a></a><td colspan=1 rowspan=1><a name=d62140e1407 class=n-a></a></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1409 class=n-a></a>Temsirolimus</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1412 class=n-a></a>MTOR</td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1415 class=n-a></a>GOG-0268, phase II<sup><a href="#ref-128">128</a></sup></td><td align=left colspan=1 rowspan=1 valign=top><a name=d62140e1421 class=n-a></a>PFS 3.2/OS 11.6</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d62140e1429 class=n-a></a><p id=fn1> <sup>a</sup>US Food and Drug Administration approval gained. <sup>b</sup>Overall survival (OS) may be underestimated; OS = 31.9 months when crossover poly-ribose polymerase (PARP) exposure post-trial is included<sup><a href="#ref-129">129</a></sup>. Italics indicate trial in progress or awaiting data analysis. GOG, Gynecologic Oncology Group; IL-12, interleukin-12; JAK, Janus Kinase; MTOR, mammalian target of rapamycin; NRG, NSABP/RTOG/GOG Collaborative Group; PD-1, programmed death 1; PFS, progression-free survival; TLR8, Toll-like receptor 8; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor 2.</p></div></div></div></div><div class=section><a name=d62140e1447 class=n-a></a><h3 class=section-title>Immunotherapy</h3><p class="" id=d62140e1452>The possible effectiveness of immunotherapeutic approaches in ovarian cancer was suggested by a 2003 study reporting that ovarian cancer patients whose tumors contained CD3<sup>+</sup> T cells experienced a higher five-year OS rate than those whose tumors did not contain those cells (38% versus 4.5%). In another approach, patients are “immunized” with tumor antigens. Although positive antibody responses have been reported, no vaccination approach has yet improved any clinically relevant outcomes in ovarian cancer<sup><a href="#ref-97">97</a>–<a href="#ref-99">99</a></sup>.</p><p class="" id=d62140e1465>In several cancer types, investigators are attempting to block programmed death 1 (PD-1), a protein that protects tumor cells from immune system attack, but so far little work has been done in this area for ovarian cancer. In a single phase II study, the anti-PD-1 antibody nivolumab produced an overall response rate of 15% (3 out of 20) and a median PFS of 3.5 months. Similarly, in a preliminary report of a phase IB study using the anti-PD-1 antibody pembrolizumab in patients with ovarian cancer that expressed the PD-1 ligand, the overall response rate was 3 out of 20<sup><a href="#ref-100">100</a></sup>. Although the overall response rate was low, two patients had complete and durable remissions of up to one year.</p></div><div class=section><a name=d62140e1473 class=n-a></a><h3 class=section-title>Conclusions</h3><p class="" id=d62140e1478>Since the incorporation of taxane-containing chemotherapy into standard treatment, the survival of patients with ovarian cancer has improved only slightly. However, the current research highlighted here gives us hope that survival rates will continue to increase as there is further development of <i>in vivo</i> mouse models, <i>in vitro</i> tumor microenvironment models, identification of pathways activated in chemoresistance, immunotherapy, optimization of chemotherapy regimens, and development of targeted agents. In addition, cost models are needed to determine the feasibility and sustainability of widespread usage of newly developed approaches.</p></div></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d62140e1 class=n-a></a><h2 class=main-title id=d62502>Competing interests</h2><p class=metadata-entry><a name=d62140e90 class=n-a></a><p id=d62140e92> The authors declare that they have no competing interests.</p></p></div><div class=back-section><a name=d62140e1 class=n-a></a><h2 class=main-title id=d62504>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d62140e1492 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d62912>References</h2><div class="section ref-list"><a name=d62140e1492 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d62140e1499 class=n-a></a>Swerdlow M: Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. <i>Am J Obstet Gynecol.</i> 1959; <b>77</b>(1): 197–200. <a target=xrefwindow id=d62140e1507 href="http://www.ncbi.nlm.nih.gov/pubmed/13606191">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1510 href="http://dx.doi.org/10.1016/0002-9378(59)90287-X">Publisher Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726071516"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e1519 class=n-a></a>Siegel RL, Miller KD, Jemal A: Cancer statistics, 2016. <i>CA Cancer J Clin.</i> 2016; <b>66</b>(1): 7–30. <a target=xrefwindow id=d62140e1527 href="http://www.ncbi.nlm.nih.gov/pubmed/26742998">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1530 href="http://dx.doi.org/10.3322/caac.21332">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726071516">F1000 Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d62140e1543 class=n-a></a>SEER Cancer Statistics Factsheets: Ovarian Cancer. National Cancer Institute. Bethesda, MD. <a target=xrefwindow id=d62140e1545 href="http://seer.cancer.gov/statfacts/html/ovary.html">Reference Source</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d62140e1554 class=n-a></a>Di Saia PJ, Creasman WT: Clinical Gynecologic Oncology. 8th ed, ed. P.J.D. Saia, et al., Philadephia, PA Elsevier/Saunders. 2012.<a target=xrefwindow id=d62140e1556 href="https://books.google.co.in/books?hl=en&amp;lr=&amp;id=xJxh22oki6UC&amp;oi=fnd&amp;pg=PP1&amp;dq=Clinical+Gynecologic+Oncology+2012&amp;ots=A5je9-wLZ8&amp;sig=lZD9IQiNimWxKwjINXuNNdeZsK4#v=onepage&amp;q&amp;f=false">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d62140e1565 class=n-a></a>Aarnio M, Sankila R, Pukkala E, <i> et al.</i>: Cancer risk in mutation carriers of DNA-mismatch-repair genes. <i>Int J Cancer.</i> 1999; <b>81</b>(2): 214–8. <a target=xrefwindow id=d62140e1576 href="http://www.ncbi.nlm.nih.gov/pubmed/10188721">PubMed Abstract </a> | <a target="xrefwindow" id="d62140e1579" href="http://dx.doi.org/10.1002/(SICI)1097-0215(19990412)81:2<214::AID-IJC8&gt;3.0.CO;2-L">Publisher Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d62140e1589 class=n-a></a>Risch HA, McLaughlin JR, Cole DE, <i> et al.</i>: Prevalence and penetrance of germline <i>BRCA1</i> and <i>BRCA2</i> mutations in a population series of 649 women with ovarian cancer. <i>Am J Hum Genet.</i> 2001; <b>68</b>(3): 700–10. <a target=xrefwindow id=d62140e1607 href="http://www.ncbi.nlm.nih.gov/pubmed/11179017">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1610 href="http://dx.doi.org/10.1086/318787">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1613 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1274482">Free Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d62140e1622 class=n-a></a>Pal T, Permuth-Wey J, Betts JA, <i> et al.</i>: <i>BRCA1</i> and <i>BRCA2</i> mutations account for a large proportion of ovarian carcinoma cases. <i>Cancer.</i> 2005; <b>104</b>(12): 2807–16. <a target=xrefwindow id=d62140e1640 href="http://www.ncbi.nlm.nih.gov/pubmed/16284991">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1643 href="http://dx.doi.org/10.1002/cncr.21536">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d62140e1652 class=n-a></a>Finch A, Beiner M, Lubinski J, <i> et al.</i>: Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a <i>BRCA1</i> or <i>BRCA2</i> Mutation. <i>JAMA.</i> 2006; <b>296</b>(2): 185–92. <a target=xrefwindow id=d62140e1670 href="http://www.ncbi.nlm.nih.gov/pubmed/16835424">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1673 href="http://dx.doi.org/10.1001/jama.296.2.185">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d62140e1682 class=n-a></a>Alvarez AA, Moore WF, Robboy SJ, <i> et al.</i>: K-ras mutations in Müllerian inclusion cysts associated with serous borderline tumors of the ovary. <i>Gynecol Oncol.</i> 2001; <b>80</b>(2): 201–6. <a target=xrefwindow id=d62140e1693 href="http://www.ncbi.nlm.nih.gov/pubmed/11161860">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1696 href="http://dx.doi.org/10.1006/gyno.2000.6066">Publisher Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14224956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e1705 class=n-a></a>Pearce CL, Templeman C, Rossing MA, <i> et al.</i>: Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. <i>Lancet Oncol.</i> 2012; <b>13</b>(4): 385–94. <a target=xrefwindow id=d62140e1716 href="http://www.ncbi.nlm.nih.gov/pubmed/22361336">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1719 href="http://dx.doi.org/10.1016/S1470-2045(11)70404-1">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1723 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3664011">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14224956">F1000 Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/2181957"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e1736 class=n-a></a>Kurman RJ, Shih I: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. <i>Am J Surg Pathol.</i> 2010; <b>34</b>(3): 433–43. <a target=xrefwindow id=d62140e1744 href="http://www.ncbi.nlm.nih.gov/pubmed/20154587">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1747 href="http://dx.doi.org/10.1097/PAS.0b013e3181cf3d79">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1750 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2841791">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/2181957">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d62140e1764 class=n-a></a>Dong A, Lu Y, Lu B: Genomic/Epigenomic Alterations in Ovarian Carcinoma: Translational Insight into Clinical Practice. <i>J Cancer.</i> 2016; <b>7</b>(11): 1441–51. <a target=xrefwindow id=d62140e1772 href="http://www.ncbi.nlm.nih.gov/pubmed/27471560">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1775 href="http://dx.doi.org/10.7150/jca.15556">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1778 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4964128">Free Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d62140e1787 class=n-a></a>Lee Y, Miron A, Drapkin R, <i> et al.</i>: A candidate precursor to serous carcinoma that originates in the distal fallopian tube. <i>J Pathol.</i> 2007; <b>211</b>(1): 26–35. <a target=xrefwindow id=d62140e1798 href="http://www.ncbi.nlm.nih.gov/pubmed/17117391">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1801 href="http://dx.doi.org/10.1002/path.2091">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d62140e1810 class=n-a></a>Crum CP, Drapkin R, Miron A, <i> et al.</i>: The distal fallopian tube: a new model for pelvic serous carcinogenesis. <i>Curr Opin Obstet Gynecol.</i> 2007; <b>19</b>(1): 3–9. <a target=xrefwindow id=d62140e1821 href="http://www.ncbi.nlm.nih.gov/pubmed/17218844">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1824 href="http://dx.doi.org/10.1097/GCO.0b013e328011a21f">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d62140e1833 class=n-a></a>Jarboe E, Folkins A, Nucci MR, <i> et al.</i>: Serous carcinogenesis in the fallopian tube: a descriptive classification. <i>Int J Gynecol Pathol.</i> 2008; <b>27</b>(1): 1–9. <a target=xrefwindow id=d62140e1844 href="http://www.ncbi.nlm.nih.gov/pubmed/18156967">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1847 href="http://dx.doi.org/10.1097/pgp.0b013e31814b191f">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d62140e1856 class=n-a></a>Carlson JW, Miron A, Jarboe EA, <i> et al.</i>: Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. <i>J Clin Oncol.</i> 2008; <b>26</b>(25): 4160–5. <a target=xrefwindow id=d62140e1867 href="http://www.ncbi.nlm.nih.gov/pubmed/18757330">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1870 href="http://dx.doi.org/10.1200/JCO.2008.16.4814">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1874 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2654373">Free Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727083495"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e1883 class=n-a></a>Eckert MA, Pan S, Hernandez KM, <i> et al.</i>: Genomics of Ovarian Cancer Progression Reveals Diverse Metastatic Trajectories Including Intraepithelial Metastasis to the Fallopian Tube. <i>Cancer Discov.</i> 2016; <b>6</b>(12): 1342–51. <a target=xrefwindow id=d62140e1894 href="http://www.ncbi.nlm.nih.gov/pubmed/27856443">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1897 href="http://dx.doi.org/10.1158/2159-8290.CD-16-0607">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1901 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5164915">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727083495">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195779"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e1915 class=n-a></a>McDaniel AS, Stall JN, Hovelson DH, <i> et al.</i>: Next-Generation Sequencing of Tubal Intraepithelial Carcinomas. <i>JAMA Oncol.</i> 2015; <b>1</b>(8): 1128–32. <a target=xrefwindow id=d62140e1926 href="http://www.ncbi.nlm.nih.gov/pubmed/26181193">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1929 href="http://dx.doi.org/10.1001/jamaoncol.2015.1618">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1933 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4935931">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195779">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/12178956"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e1946 class=n-a></a>Cancer Genome Atlas Research Network: Integrated genomic analyses of ovarian carcinoma. <i>Nature.</i> 2011; <b>474</b>(7353): 609–15. <a target=xrefwindow id=d62140e1954 href="http://www.ncbi.nlm.nih.gov/pubmed/21720365">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1957 href="http://dx.doi.org/10.1038/nature10166">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1960 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3163504">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/12178956">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a name=d62140e1973 class=n-a></a>Vang R, Levine DA, Soslow RA, <i> et al.</i>: Molecular Alterations of <i>TP53</i> are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking <i>TP53</i> Mutations in The Cancer Genome Atlas Ovarian Study. <i>Int J Gynecol Pathol.</i> 2016; <b>35</b>(1): 48–55. <a target=xrefwindow id=d62140e1991 href="http://www.ncbi.nlm.nih.gov/pubmed/26166714">PubMed Abstract </a> | <a target=xrefwindow id=d62140e1994 href="http://dx.doi.org/10.1097/PGP.0000000000000207">Publisher Full Text </a> | <a target=xrefwindow id=d62140e1997 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4696053">Free Full Text </a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195781"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2006 class=n-a></a>Norquist BM, Harrell MI, Brady MF, <i> et al.</i>: Inherited Mutations in Women With Ovarian Carcinoma. <i>JAMA Oncol.</i> 2016; <b>2</b>(4): 482–90. <a target=xrefwindow id=d62140e2017 href="http://www.ncbi.nlm.nih.gov/pubmed/26720728">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2020 href="http://dx.doi.org/10.1001/jamaoncol.2015.5495">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2024 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4845939">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195781">F1000 Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d62140e2037 class=n-a></a>Loveday C, Turnbull C, Ramsay E, <i> et al.</i>: Germline mutations in <i>RAD51D</i> confer susceptibility to ovarian cancer. <i>Nat Genet.</i> 2011; <b>43</b>(9): 879–82. <a target=xrefwindow id=d62140e2051 href="http://www.ncbi.nlm.nih.gov/pubmed/21822267">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2055 href="http://dx.doi.org/10.1038/ng.893">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2058 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4845885">Free Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d62140e2067 class=n-a></a>Loveday C, Turnbull C, Ruark E, <i> et al.</i>: Germline RAD51C mutations confer susceptibility to ovarian cancer. <i>Nat Genet.</i> 2012; <b>44</b>(5): 475–6; author reply 476. <a target=xrefwindow id=d62140e2078 href="http://www.ncbi.nlm.nih.gov/pubmed/22538716">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2081 href="http://dx.doi.org/10.1038/ng.2224">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d62140e2091 class=n-a></a>Meindl A, Hellebrand H, Wiek C, <i> et al.</i>: Germline mutations in breast and ovarian cancer pedigrees establish <i>RAD51C</i> as a human cancer susceptibility gene. <i>Nat Genet.</i> 2010; <b>42</b>(5): 410–4. <a target=xrefwindow id=d62140e2105 href="http://www.ncbi.nlm.nih.gov/pubmed/20400964">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2109 href="http://dx.doi.org/10.1038/ng.569">Publisher Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725755674"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2118 class=n-a></a>Ramus SJ, Song H, Dicks E, <i> et al.</i>: Germline Mutations in the <i>BRIP1, BARD1, PALB2,</i> and <i>NBN</i> Genes in Women With Ovarian Cancer. <i>J Natl Cancer Inst.</i> 2015; <b>107</b>(11): pii: djv214. <a target=xrefwindow id=d62140e2136 href="http://www.ncbi.nlm.nih.gov/pubmed/26315354">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2139 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4643629">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725755674">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717968386"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2152 class=n-a></a>Walsh T, Casadei S, Lee MK, <i> et al.</i>: Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. <i>Proc Natl Acad Sci U S A.</i> 2011; <b>108</b>(44): 18032–7. <a target=xrefwindow id=d62140e2163 href="http://www.ncbi.nlm.nih.gov/pubmed/22006311">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2166 href="http://dx.doi.org/10.1073/pnas.1115052108">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2170 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3207658">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717968386">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d62140e2183 class=n-a></a>Genetic/Familial High-Risk Assessment: Breast and Ovarian V. 1.2017. <i>NCCN Clinical Practice Guidelines in Oncology</i>. 2016. <a target=xrefwindow id=d62140e2188 href="https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf">Reference Source</a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725521376"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2197 class=n-a></a>Patch A, Christie EL, Etemadmoghadam D, <i> et al.</i>: Whole-genome characterization of chemoresistant ovarian cancer. <i>Nature.</i> 2015; <b>521</b>(7553): 489–94. <a target=xrefwindow id=d62140e2208 href="http://www.ncbi.nlm.nih.gov/pubmed/26017449">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2211 href="http://dx.doi.org/10.1038/nature14410">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725521376">F1000 Recommendation</a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718490430"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2224 class=n-a></a>Pradeep S, Kim SW, Wu SY, <i> et al.</i>: Hematogenous metastasis of ovarian cancer: rethinking mode of spread. <i>Cancer Cell.</i> 2014; <b>26</b>(1): 77–91. <a target=xrefwindow id=d62140e2235 href="http://www.ncbi.nlm.nih.gov/pubmed/25026212">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2238 href="http://dx.doi.org/10.1016/j.ccr.2014.05.002">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2242 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4100212">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718490430">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/13370054"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2256 class=n-a></a>Nieman KM, Kenny HA, Penicka CV, <i> et al.</i>: Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. <i>Nat Med.</i> 2011; <b>17</b>(11): 1498–503. <a target=xrefwindow id=d62140e2267 href="http://www.ncbi.nlm.nih.gov/pubmed/22037646">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2270 href="http://dx.doi.org/10.1038/nm.2492">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2274 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4157349">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/13370054">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d62140e2287 class=n-a></a>Hansen JM, Coleman RL, Sood AK: Targeting the tumour microenvironment in ovarian cancer. <i>Eur J Cancer.</i> 2016; <b>56</b>: 131–43. <a target=xrefwindow id=d62140e2295 href="http://www.ncbi.nlm.nih.gov/pubmed/26849037">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2298 href="http://dx.doi.org/10.1016/j.ejca.2015.12.016">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2301 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4769921">Free Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d62140e2310 class=n-a></a>Li H, Fan X, Houghton J: Tumor microenvironment: the role of the tumor stroma in cancer. <i>J Cell Biochem.</i> 2007; <b>101</b>(4): 805–15. <a target=xrefwindow id=d62140e2318 href="http://www.ncbi.nlm.nih.gov/pubmed/17226777">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2321 href="http://dx.doi.org/10.1002/jcb.21159">Publisher Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d62140e2330 class=n-a></a>Kalluri R, Zeisberg M: Fibroblasts in cancer. <i>Nat Rev Cancer.</i> 2006; <b>6</b>(5): 392–401. <a target=xrefwindow id=d62140e2338 href="http://www.ncbi.nlm.nih.gov/pubmed/16572188">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2341 href="http://dx.doi.org/10.1038/nrc1877">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718071752"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2350 class=n-a></a>Lengyel E, Burdette JE, Kenny HA, <i> et al.</i>: Epithelial ovarian cancer experimental models. <i>Oncogene.</i> 2014; <b>33</b>(28): 3619–33. <a target=xrefwindow id=d62140e2361 href="http://www.ncbi.nlm.nih.gov/pubmed/23934194">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2364 href="http://dx.doi.org/10.1038/onc.2013.321">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2368 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3990646">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718071752">F1000 Recommendation</a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718362420"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2381 class=n-a></a>Davidowitz RA, Selfors LM, Iwanicki MP, <i> et al.</i>: Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. <i>J Clin Invest.</i> 2014; <b>124</b>(6): 2611–25. <a target=xrefwindow id=d62140e2392 href="http://www.ncbi.nlm.nih.gov/pubmed/24762435">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2395 href="http://dx.doi.org/10.1172/JCI69815">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2399 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4038562">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718362420">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a name=d62140e2413 class=n-a></a>Rankin EB, Fuh KC, Taylor TE, <i> et al.</i>: AXL is an essential factor and therapeutic target for metastatic ovarian cancer. <i>Cancer Res.</i> 2010; <b>70</b>(19): 7570–9. <a target=xrefwindow id=d62140e2424 href="http://www.ncbi.nlm.nih.gov/pubmed/20858715">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2427 href="http://dx.doi.org/10.1158/0008-5472.CAN-10-1267">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2431 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3408227">Free Full Text </a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a name=d62140e2440 class=n-a></a>Divine LM, Nguyen MR, Meller E, <i> et al.</i>: AXL modulates extracellular matrix protein expression and is essential for invasion and metastasis in endometrial cancer. <i>Oncotarget.</i> 2016; <b>7</b>(47): 77291–77305. <a target=xrefwindow id=d62140e2451 href="http://www.ncbi.nlm.nih.gov/pubmed/27764792">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2454 href="http://dx.doi.org/10.18632/oncotarget.12637">Publisher Full Text </a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726277306"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2463 class=n-a></a>Haemmerle M, Bottsford-Miller J, Pradeep S, <i> et al.</i>: FAK regulates platelet extravasation and tumor growth after antiangiogenic therapy withdrawal. <i>J Clin Invest.</i> 2016; <b>126</b>(5): 1885–96. <a target=xrefwindow id=d62140e2474 href="http://www.ncbi.nlm.nih.gov/pubmed/27064283">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2477 href="http://dx.doi.org/10.1172/JCI85086">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4855933">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726277306">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d62140e2494 class=n-a></a>Flesken-Nikitin A, Choi K, Eng JP, <i> et al.</i>: Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. <i>Cancer Res.</i> 2003; <b>63</b>(13): 3459–63. <a target=xrefwindow id=d62140e2505 href="http://www.ncbi.nlm.nih.gov/pubmed/12839925">PubMed Abstract </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1045"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2514 class=n-a></a>Dinulescu DM, Ince TA, Quade BJ, <i> et al.</i>: Role of <i>K-ras</i> and <i>Pten</i> in the development of mouse models of endometriosis and endometrioid ovarian cancer. <i>Nat Med.</i> 2005; <b>11</b>(1): 63–70. <a target=xrefwindow id=d62140e2532 href="http://www.ncbi.nlm.nih.gov/pubmed/15619626">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2535 href="http://dx.doi.org/10.1038/nm1173">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1045">F1000 Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d62140e2548 class=n-a></a>Wu R, Baker SJ, Hu TC, <i> et al.</i>: Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer. <i>Am J Pathol.</i> 2013; <b>182</b>(4): 1391–9. <a target=xrefwindow id=d62140e2559 href="http://www.ncbi.nlm.nih.gov/pubmed/23499052">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2562 href="http://dx.doi.org/10.1016/j.ajpath.2012.12.031">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2566 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3620412">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d62140e2576 class=n-a></a>Wu R, Hu TC, Rehemtulla A, <i> et al.</i>: Preclinical testing of PI3K/AKT/mTOR signaling inhibitors in a mouse model of ovarian endometrioid adenocarcinoma. <i>Clin Cancer Res.</i> 2011; <b>17</b>(23): 7359–72. <a target=xrefwindow id=d62140e2587 href="http://www.ncbi.nlm.nih.gov/pubmed/21903772">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2590 href="http://dx.doi.org/10.1158/1078-0432.CCR-11-1388">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2594 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3229658">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d62140e2603 class=n-a></a>Kim J, Coffey DM, Creighton CJ, <i> et al.</i>: High-grade serous ovarian cancer arises from fallopian tube in a mouse model. <i>Proc Natl Acad Sci U S A.</i> 2012; <b>109</b>(10): 3921–6. <a target=xrefwindow id=d62140e2614 href="http://www.ncbi.nlm.nih.gov/pubmed/22331912">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2617 href="http://dx.doi.org/10.1073/pnas.1117135109">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2621 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3309733">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10351"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2630 class=n-a></a>Connolly DC, Bao R, Nikitin AY, <i> et al.</i>: Female mice chimeric for expression of the simian virus 40 TAg under control of the <i>MISIIR</i> promoter develop epithelial ovarian cancer. <i>Cancer Res.</i> 2003; <b>63</b>(6): 1389–97. <a target=xrefwindow id=d62140e2644 href="http://www.ncbi.nlm.nih.gov/pubmed/12649204">PubMed Abstract </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10351">F1000 Recommendation</a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718319980"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2657 class=n-a></a>Sherman-Baust CA, Kuhn E, Valle BL, <i> et al.</i>: A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. <i>J Pathol.</i> 2014; <b>233</b>(3): 228–37. <a target=xrefwindow id=d62140e2668 href="http://www.ncbi.nlm.nih.gov/pubmed/24652535">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2671 href="http://dx.doi.org/10.1002/path.4353">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2675 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4149901">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718319980">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718206954"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2688 class=n-a></a>Perets R, Wyant GA, Muto KW, <i> et al.</i>: Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in <i>Brca;Tp53;Pten</i> models. <i>Cancer Cell.</i> 2013; <b>24</b>(6): 751–65. <a target=xrefwindow id=d62140e2702 href="http://www.ncbi.nlm.nih.gov/pubmed/24332043">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2706 href="http://dx.doi.org/10.1016/j.ccr.2013.10.013">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2709 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3917315">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718206954">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726647763"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2722 class=n-a></a>Walton J, Blagih J, Ennis D, <i> et al.</i>: CRISPR/Cas9-Mediated <i>Trp53</i> and <i>Brca2</i> Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma. <i>Cancer Res.</i> 2016; <b>76</b>(20): 6118–29. <a target=xrefwindow id=d62140e2740 href="http://www.ncbi.nlm.nih.gov/pubmed/27530326">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2743 href="http://dx.doi.org/10.1158/0008-5472.CAN-16-1272">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726647763">F1000 Recommendation</a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718369342"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2757 class=n-a></a>Topp MD, Hartley L, Cook M, <i> et al.</i>: Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. <i>Mol Oncol.</i> 2014; <b>8</b>(3): 656–68. <a target=xrefwindow id=d62140e2768 href="http://www.ncbi.nlm.nih.gov/pubmed/24560445">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2771 href="http://dx.doi.org/10.1016/j.molonc.2014.01.008">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2775 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4400120">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718369342">F1000 Recommendation</a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718231106"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2788 class=n-a></a>Weroha SJ, Becker MA, Enderica-Gonzalez S, <i> et al.</i>: Tumorgrafts as <i>in vivo</i> surrogates for women with ovarian cancer. <i>Clin Cancer Res.</i> 2014; <b>20</b>(5): 1288–97. <a target=xrefwindow id=d62140e2802 href="http://www.ncbi.nlm.nih.gov/pubmed/24398046">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2806 href="http://dx.doi.org/10.1158/1078-0432.CCR-13-2611">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2809 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3947430">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718231106">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718872736"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2822 class=n-a></a>Dobbin ZC, Katre AA, Steg AD, <i> et al.</i>: Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer. <i>Oncotarget.</i> 2014; <b>5</b>(18): 8750–64. <a target=xrefwindow id=d62140e2833 href="http://www.ncbi.nlm.nih.gov/pubmed/25209969">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2836 href="http://dx.doi.org/10.18632/oncotarget.2373">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2840 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4226719">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718872736">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726696639"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2853 class=n-a></a>Liu JF, Palakurthi S, Zeng Q, <i> et al.</i>: Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. <i>Clin Cancer Res.</i> 2016. <a target=xrefwindow id=d62140e2861 href="http://www.ncbi.nlm.nih.gov/pubmed/27573169">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2864 href="http://dx.doi.org/10.1158/1078-0432.CCR-16-1237">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726696639">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d62140e2877 class=n-a></a>Ovarian Cancer Screening Tests: Safety Communication - FDA Recommends Against Use. 2016. <a target=xrefwindow id=d62140e2879 href="http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm519540.htm">Reference Source</a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d62140e2888 class=n-a></a>Moyer VA, U.S. Preventive Services Task Force: Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. <i>Ann Intern Med.</i> 2012; <b>157</b>(12): 900–4. <a target=xrefwindow id=d62140e2896 href="http://www.ncbi.nlm.nih.gov/pubmed/22964825">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2899 href="http://dx.doi.org/10.7326/0003-4819-157-11-201212040-00539">Publisher Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d62140e2909 class=n-a></a>Buys SS, Partridge E, Greene MH, <i> et al.</i>: Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. <i>Am J Obstet Gynecol.</i> 2005; <b>193</b>(5): 1630–9. <a target=xrefwindow id=d62140e2920 href="http://www.ncbi.nlm.nih.gov/pubmed/16260202">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2923 href="http://dx.doi.org/10.1016/j.ajog.2005.05.005">Publisher Full Text </a></span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726042505"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e2932 class=n-a></a>Jacobs IJ, Menon U, Ryan A, <i> et al.</i>: Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. <i>Lancet.</i> 2016; <b>387</b>(10022): 945–56. <a target=xrefwindow id=d62140e2943 href="http://www.ncbi.nlm.nih.gov/pubmed/26707054">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2946 href="http://dx.doi.org/10.1016/S0140-6736(15)01224-6">Publisher Full Text </a> | <a target=xrefwindow id=d62140e2950 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4779792">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726042505">F1000 Recommendation</a></span></li><li><a name=ref-56 class=n-a></a><span class=label>56. </span>&nbsp;<span class=citation><a name=d62140e2963 class=n-a></a>Kobayashi H, Yamada Y, Sado T, <i> et al.</i>: A randomized study of screening for ovarian cancer: a multicenter study in Japan. <i>Int J Gynecol Cancer.</i> 2008; <b>18</b>(3): 414–20. <a target=xrefwindow id=d62140e2974 href="http://www.ncbi.nlm.nih.gov/pubmed/17645503">PubMed Abstract </a> | <a target=xrefwindow id=d62140e2977 href="http://dx.doi.org/10.1111/j.1525-1438.2007.01035.x">Publisher Full Text </a></span></li><li><a name=ref-57 class=n-a></a><span class=label>57. </span>&nbsp;<span class=citation><a name=d62140e2986 class=n-a></a>Rosenthal AN, Fraser L, Manchanda R, <i> et al.</i>: Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. <i>J Clin Oncol.</i> 2013; <b>31</b>(1): 49–57. <a target=xrefwindow id=d62140e2997 href="http://www.ncbi.nlm.nih.gov/pubmed/23213100">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3000 href="http://dx.doi.org/10.1200/JCO.2011.39.7638">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3004 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3530690">Free Full Text </a></span></li><li><a name=ref-58 class=n-a></a><span class=label>58. </span>&nbsp;<span class=citation><a name=d62140e3013 class=n-a></a>Easton DF, Ford D, Bishop DT: Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. <i>Am J Hum Genet.</i> 1995; <b>56</b>(1): 265–71. <a target=xrefwindow id=d62140e3021 href="http://www.ncbi.nlm.nih.gov/pubmed/7825587">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3024 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1801337">Free Full Text </a></span></li><li><a name=ref-59 class=n-a></a><span class=label>59. </span>&nbsp;<span class=citation><a name=d62140e3033 class=n-a></a>Brose MS, Rebbeck TR, Calzone KA, <i> et al.</i>: Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. <i>J Natl Cancer Inst.</i> 2002; <b>94</b>(18): 1365–72. <a target=xrefwindow id=d62140e3044 href="http://www.ncbi.nlm.nih.gov/pubmed/12237282">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3047 href="http://dx.doi.org/10.1093/jnci/94.18.1365">Publisher Full Text </a></span></li><li><a name=ref-60 class=n-a></a><span class=label>60. </span>&nbsp;<span class=citation><a name=d62140e3057 class=n-a></a>Chen S, Parmigiani G: Meta-analysis of <i>BRCA1</i> and <i>BRCA2</i> penetrance. <i>J Clin Oncol.</i> 2007; <b>25</b>(11): 1329–33. <a target=xrefwindow id=d62140e3071 href="http://www.ncbi.nlm.nih.gov/pubmed/17416853">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3075 href="http://dx.doi.org/10.1200/JCO.2006.09.1066">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3078 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2267287">Free Full Text </a></span></li><li><a name=ref-61 class=n-a></a><span class=label>61. </span>&nbsp;<span class=citation><a name=d62140e3087 class=n-a></a>Levy-Lahad E, Friedman E: Cancer risks among <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Br J Cancer.</i> 2007; <b>96</b>(1): 11–5. <a target=xrefwindow id=d62140e3101 href="http://www.ncbi.nlm.nih.gov/pubmed/17213823">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3105 href="http://dx.doi.org/10.1038/sj.bjc.6603535">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3108 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2360226">Free Full Text </a></span></li><li><a name=ref-62 class=n-a></a><span class=label>62. </span>&nbsp;<span class=citation><a name=d62140e3117 class=n-a></a>Antoniou A, Pharoah PD, Narod S, <i> et al.</i>: Average risks of breast and ovarian cancer associated with <i>BRCA1</i> or <i>BRCA2</i> mutations detected in case Series unselected for family history: a combined analysis of 22 studies. <i>Am J Hum Genet.</i> 2003; <b>72</b>(5): 1117–30. <a target=xrefwindow id=d62140e3135 href="http://www.ncbi.nlm.nih.gov/pubmed/12677558">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3138 href="http://dx.doi.org/10.1086/375033">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3141 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1180265">Free Full Text </a></span></li><li><a name=ref-63 class=n-a></a><span class=label>63. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726008518"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3150 class=n-a></a>Møller P, Seppälä T, Bernstein I, <i> et al.</i>: Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. <i>Gut.</i> 2015; pii: gutjnl-2015-309675. <a target=xrefwindow id=d62140e3158 href="http://www.ncbi.nlm.nih.gov/pubmed/26657901">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3161 href="http://dx.doi.org/10.1136/gutjnl-2015-309675">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726008518">F1000 Recommendation</a></span></li><li><a name=ref-64 class=n-a></a><span class=label>64. </span>&nbsp;<span class=citation><a name=d62140e3174 class=n-a></a>Berek JS, Chalas E, Edelson M, <i> et al.</i>: Prophylactic and risk-reducing bilateral salpingo-oophorectomy: recommendations based on risk of ovarian cancer. <i>Obstet Gynecol.</i> 2010; <b>116</b>(3): 733–43. <a target=xrefwindow id=d62140e3185 href="http://www.ncbi.nlm.nih.gov/pubmed/20733460">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3188 href="http://dx.doi.org/10.1097/AOG.0b013e3181ec5fc1">Publisher Full Text </a></span></li><li><a name=ref-65 class=n-a></a><span class=label>65. </span>&nbsp;<span class=citation><a name=d62140e3197 class=n-a></a>Greene MH, Piedmonte M, Alberts D, <i> et al.</i>: A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study. <i>Cancer Epidemiol Biomarkers Prev.</i> 2008; <b>17</b>(3): 594–604. <a target=xrefwindow id=d62140e3208 href="http://www.ncbi.nlm.nih.gov/pubmed/18349277">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3211 href="http://dx.doi.org/10.1158/1055-9965.EPI-07-2703">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3215 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3125978">Free Full Text </a></span></li><li><a name=ref-66 class=n-a></a><span class=label>66. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726343083"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3225 class=n-a></a>Harmsen MG, IntHout J, Arts-de Jong M, <i> et al.</i>: Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk. <i>Obstet Gynecol.</i> 2016; <b>127</b>(6): 1054–63. <a target=xrefwindow id=d62140e3236 href="http://www.ncbi.nlm.nih.gov/pubmed/27159752">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3239 href="http://dx.doi.org/10.1097/AOG.0000000000001448">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726343083">F1000 Recommendation</a></span></li><li><a name=ref-67 class=n-a></a><span class=label>67. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717970145"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3252 class=n-a></a>Kwon JS, Tinker A, Pansegrau G, <i> et al.</i>: Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. <i>Obstet Gynecol.</i> 2013; <b>121</b>(1): 14–24. <a target=xrefwindow id=d62140e3263 href="http://www.ncbi.nlm.nih.gov/pubmed/23232752">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3266 href="http://dx.doi.org/10.1097/AOG.0b013e3182783c2f">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717970145">F1000 Recommendation</a></span></li><li><a name=ref-68 class=n-a></a><span class=label>68. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725919299"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3279 class=n-a></a>Tucker PE, Bulsara MK, Salfinger SG, <i> et al.</i>: Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. <i>Gynecol Oncol.</i> 2016; <b>140</b>(1): 95–100. <a target=xrefwindow id=d62140e3290 href="http://www.ncbi.nlm.nih.gov/pubmed/26545955">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3293 href="http://dx.doi.org/10.1016/j.ygyno.2015.11.002">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725919299">F1000 Recommendation</a></span></li><li><a name=ref-69 class=n-a></a><span class=label>69. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725957592"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3306 class=n-a></a>Johansen N, Liavaag AH, Tanbo TG, <i> et al.</i>: Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. <i>Gynecol Oncol.</i> 2016; <b>140</b>(1): 101–6. <a target=xrefwindow id=d62140e3317 href="http://www.ncbi.nlm.nih.gov/pubmed/26597462">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3320 href="http://dx.doi.org/10.1016/j.ygyno.2015.11.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725957592">F1000 Recommendation</a></span></li><li><a name=ref-70 class=n-a></a><span class=label>70. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10182961"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3333 class=n-a></a>Finch A, Metcalfe KA, Chiang JK, <i> et al.</i>: The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. <i>Gynecol Oncol.</i> 2011; <b>121</b>(1): 163–8. <a target=xrefwindow id=d62140e3344 href="http://www.ncbi.nlm.nih.gov/pubmed/21216453">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3347 href="http://dx.doi.org/10.1016/j.ygyno.2010.12.326">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10182961">F1000 Recommendation</a></span></li><li><a name=ref-71 class=n-a></a><span class=label>71. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726127533"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3360 class=n-a></a>Birrer N, Chinchilla C, Del Carmen M, <i> et al.</i>: Is Hormone Replacement Therapy Safe in Women With a BRCA Mutation?: A Systematic Review of the Contemporary Literature. <i>Am J Clin Oncol.</i> 2016. <a target=xrefwindow id=d62140e3368 href="http://www.ncbi.nlm.nih.gov/pubmed/26840041">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3371 href="http://dx.doi.org/10.1097/COC.0000000000000269">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726127533">F1000 Recommendation</a></span></li><li><a name=ref-72 class=n-a></a><span class=label>72. </span>&nbsp;<span class=citation><a name=d62140e3385 class=n-a></a>Markman M, Bundy BN, Alberts DS, <i> et al.</i>: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. <i>J Clin Oncol.</i> 2001; <b>19</b>(4): 1001–7. <a target=xrefwindow id=d62140e3396 href="http://www.ncbi.nlm.nih.gov/pubmed/11181662">PubMed Abstract </a></span></li><li><a name=ref-73 class=n-a></a><span class=label>73. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/10235"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3405 class=n-a></a>Armstrong DK, Bundy B, Wenzel L, <i> et al.</i>: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. <i>N Engl J Med.</i> 2006; <b>354</b>(1): 34–43. <a target=xrefwindow id=d62140e3416 href="http://www.ncbi.nlm.nih.gov/pubmed/16394300">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3419 href="http://dx.doi.org/10.1056/NEJMoa052985">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/10235">F1000 Recommendation</a></span></li><li><a name=ref-74 class=n-a></a><span class=label>74. </span>&nbsp;<span class=citation><a name=d62140e3432 class=n-a></a>Wright AA, Cronin A, Milne DE, <i> et al.</i>: Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. <i>J Clin Oncol.</i> 2015; <b>33</b>(26): 2841–7. <a target=xrefwindow id=d62140e3443 href="http://www.ncbi.nlm.nih.gov/pubmed/26240233">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3446 href="http://dx.doi.org/10.1200/JCO.2015.61.4776">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3450 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4554746">Free Full Text </a></span></li><li><a name=ref-75 class=n-a></a><span class=label>75. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718078524"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3459 class=n-a></a>Katsumata N, Yasuda M, Isonishi S, <i> et al.</i>: Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial. <i>Lancet Oncol.</i> 2013; <b>14</b>(10): 1020–6. <a target=xrefwindow id=d62140e3470 href="http://www.ncbi.nlm.nih.gov/pubmed/23948349">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3473 href="http://dx.doi.org/10.1016/S1470-2045(13)70363-2">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718078524">F1000 Recommendation</a></span></li><li><a name=ref-76 class=n-a></a><span class=label>76. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/14021994"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3486 class=n-a></a>Burger RA, Brady MF, Bookman MA, <i> et al.</i>: Incorporation of bevacizumab in the primary treatment of ovarian cancer. <i>N Engl J Med.</i> 2011; <b>365</b>(26): 2473–83. <a target=xrefwindow id=d62140e3497 href="http://www.ncbi.nlm.nih.gov/pubmed/22204724">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3500 href="http://dx.doi.org/10.1056/NEJMoa1104390">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/14021994">F1000 Recommendation</a></span></li><li><a name=ref-77 class=n-a></a><span class=label>77. </span>&nbsp;<span class=citation><a name=d62140e3513 class=n-a></a>Walker JL, Brady MF, DiSilvestro PA, <i> et al.</i>: A phase III trial of bevacizumab with IV versus IP chemotherapy for ovarian, fallopian tube, and peritoneal carcinoma: An NRG Oncology Study. Society of Gynecologic Oncology 47th Annual Meeting. <i>J Clin Oncol.</i> 2016; <b>141</b>(Supplement 1): 208. <a target=xrefwindow id=d62140e3524 href="http://dx.doi.org/10.1016/j.ygyno.2016.04.535">Publisher Full Text </a></span></li><li><a name=ref-78 class=n-a></a><span class=label>78. </span>&nbsp;<span class=citation><a name=d62140e3534 class=n-a></a>Bristow RE, Tomacruz RS, Armstrong DK, <i> et al.</i>: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. <i>J Clin Oncol.</i> 2002; <b>20</b>(5): 1248–59. <a target=xrefwindow id=d62140e3545 href="http://www.ncbi.nlm.nih.gov/pubmed/11870167">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3548 href="http://dx.doi.org/10.1200/JCO.20.5.1248">Publisher Full Text </a></span></li><li><a name=ref-79 class=n-a></a><span class=label>79. </span>&nbsp;<span class=citation><a name=d62140e3557 class=n-a></a>Aletti GD, Dowdy SC, Gostout BS, <i> et al.</i>: Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. <i>Obstet Gynecol.</i> 2006; <b>107</b>(1): 77–85. <a target=xrefwindow id=d62140e3568 href="http://www.ncbi.nlm.nih.gov/pubmed/16394043">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3571 href="http://dx.doi.org/10.1097/01.AOG.0000192407.04428.bb">Publisher Full Text </a></span></li><li><a name=ref-80 class=n-a></a><span class=label>80. </span>&nbsp;<span class=citation><a name=d62140e3580 class=n-a></a>Chang SJ, Hodeib M, Chang J, <i> et al.</i>: Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. <i>Gynecol Oncol.</i> 2013; <b>130</b>(3): 493–8. <a target=xrefwindow id=d62140e3591 href="http://www.ncbi.nlm.nih.gov/pubmed/23747291">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3594 href="http://dx.doi.org/10.1016/j.ygyno.2013.05.040">Publisher Full Text </a></span></li><li><a name=ref-81 class=n-a></a><span class=label>81. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/6000962"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3603 class=n-a></a>Vergote I, Tropé CG, Amant F, <i> et al.</i>: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. <i>N Engl J Med.</i> 2010; <b>363</b>(10): 943–53. <a target=xrefwindow id=d62140e3614 href="http://www.ncbi.nlm.nih.gov/pubmed/20818904">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3617 href="http://dx.doi.org/10.1056/NEJMoa0908806">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/6000962">F1000 Recommendation</a></span></li><li><a name=ref-82 class=n-a></a><span class=label>82. </span>&nbsp;<span class=citation><a name=d62140e3630 class=n-a></a>Kehoe S, Hook J, Nankivell M, <i> et al.</i>: Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. <i>Lancet.</i> 2015; <b>386</b>(9990): 249–57. <a target=xrefwindow id=d62140e3641 href="http://www.ncbi.nlm.nih.gov/pubmed/26002111">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3644 href="http://dx.doi.org/10.1016/S0140-6736(14)62223-6">Publisher Full Text </a></span></li><li><a name=ref-83 class=n-a></a><span class=label>83. </span>&nbsp;<span class=citation><a name=d62140e3653 class=n-a></a>Fagotti A, Ferrandina G, Vizzielli G, <i> et al.</i>: Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome. <i>Eur J Cancer.</i> 2016; <b>59</b>: 22–33. <a target=xrefwindow id=d62140e3664 href="http://www.ncbi.nlm.nih.gov/pubmed/26998845">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3667 href="http://dx.doi.org/10.1016/j.ejca.2016.01.017">Publisher Full Text </a></span></li><li><a name=ref-84 class=n-a></a><span class=label>84. </span>&nbsp;<span class=citation><a name=d62140e3677 class=n-a></a>Onda T, Satoh T, Saito T, <i> et al.</i>: Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. <i>Eur J Cancer.</i> 2016; <b>64</b>: 22–31. <a target=xrefwindow id=d62140e3688 href="http://www.ncbi.nlm.nih.gov/pubmed/27323348">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3691 href="http://dx.doi.org/10.1016/j.ejca.2016.05.017">Publisher Full Text </a></span></li><li><a name=ref-85 class=n-a></a><span class=label>85. </span>&nbsp;<span class=citation><a name=d62140e3700 class=n-a></a>Bristow RE, Chi DS: Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. <i>Gynecol Oncol.</i> 2006; <b>103</b>(3): 1070–6. <a target=xrefwindow id=d62140e3708 href="http://www.ncbi.nlm.nih.gov/pubmed/16875720">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3711 href="http://dx.doi.org/10.1016/j.ygyno.2006.06.025">Publisher Full Text </a></span></li><li><a name=ref-86 class=n-a></a><span class=label>86. </span>&nbsp;<span class=citation><a name=d62140e3720 class=n-a></a>Chi DS, Musa F, Dao F, <i> et al.</i>: An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT). <i>Gynecol Oncol.</i> 2012; <b>124</b>(1): 10–4. <a target=xrefwindow id=d62140e3731 href="http://www.ncbi.nlm.nih.gov/pubmed/21917306">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3734 href="http://dx.doi.org/10.1016/j.ygyno.2011.08.014">Publisher Full Text </a></span></li><li><a name=ref-87 class=n-a></a><span class=label>87. </span>&nbsp;<span class=citation><a name=d62140e3743 class=n-a></a>Rauh-Hain JA, Nitschmann CC, Worley MJ Jr, <i> et al.</i>: Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma. <i>Gynecol Oncol.</i> 2013; <b>129</b>(1): 63–8. <a target=xrefwindow id=d62140e3754 href="http://www.ncbi.nlm.nih.gov/pubmed/23337490">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3757 href="http://dx.doi.org/10.1016/j.ygyno.2013.01.009">Publisher Full Text </a></span></li><li><a name=ref-88 class=n-a></a><span class=label>88. </span>&nbsp;<span class=citation><a name=d62140e3766 class=n-a></a>Petrillo M, Ferrandina G, Fagotti A, <i> et al.</i>: Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. <i>Ann Surg Oncol.</i> 2013; <b>20</b>(12): 3955–60. <a target=xrefwindow id=d62140e3777 href="http://www.ncbi.nlm.nih.gov/pubmed/23838915 ">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3780 href="http://dx.doi.org/10.1245/s10434-013-3091-6">Publisher Full Text </a></span></li><li><a name=ref-89 class=n-a></a><span class=label>89. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725517154"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3789 class=n-a></a>da Costa AA, Valadares CV, Baiocchi G, <i> et al.</i>: Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer. <i>Ann Surg Oncol.</i> 2015; <b>22</b>(Suppl 3): S971–8. <a target=xrefwindow id=d62140e3800 href="http://www.ncbi.nlm.nih.gov/pubmed/26014155">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3803 href="http://dx.doi.org/10.1245/s10434-015-4623-z">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725517154">F1000 Recommendation</a></span></li><li><a name=ref-90 class=n-a></a><span class=label>90. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727195788"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3817 class=n-a></a>Gadducci A, Cosio S, Zizioli V, <i> et al.</i>: Patterns of Recurrence and Clinical Outcome of Patients With Stage IIIC to Stage IV Epithelial Ovarian Cancer in Complete Response After Primary Debulking Surgery Plus Chemotherapy or Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery: An Italian Multicenter Retrospective Study. <i>Int J Gynecol Cancer.</i> 2017; <b>27</b>(1): 28–36. <a target=xrefwindow id=d62140e3828 href="http://www.ncbi.nlm.nih.gov/pubmed/27870700">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3831 href="http://dx.doi.org/10.1097/IGC.0000000000000843">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727195788">F1000 Recommendation</a></span></li><li><a name=ref-91 class=n-a></a><span class=label>91. </span>&nbsp;<span class=citation><a name=d62140e3844 class=n-a></a>Landen CN Jr, Goodman B, Katre AA, <i> et al.</i>: Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. <i>Mol Cancer Ther.</i> 2010; <b>9</b>(12): 3186–99. <a target=xrefwindow id=d62140e3855 href="http://www.ncbi.nlm.nih.gov/pubmed/20889728">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3858 href="http://dx.doi.org/10.1158/1535-7163.MCT-10-0563">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3862 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3005138">Free Full Text </a></span></li><li><a name=ref-92 class=n-a></a><span class=label>92. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726584438"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3871 class=n-a></a>Zhang Y, Sriraman SK, Kenny HA, <i> et al.</i>: Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform. <i>Mol Cancer Ther.</i> 2016; <b>15</b>(10): 2282–93. <a target=xrefwindow id=d62140e3882 href="http://www.ncbi.nlm.nih.gov/pubmed/27466355">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3885 href="http://dx.doi.org/10.1158/1535-7163.MCT-15-0986">Publisher Full Text </a> | <a target=xrefwindow id=d62140e3889 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5050109">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726584438">F1000 Recommendation</a></span></li><li><a name=ref-93 class=n-a></a><span class=label>93. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726136490"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3902 class=n-a></a>Han HD, Cho YJ, Cho SK, <i> et al.</i>: Linalool-Incorporated Nanoparticles as a Novel Anticancer Agent for Epithelial Ovarian Carcinoma. <i>Mol Cancer Ther.</i> 2016; <b>15</b>(4): 618–27. <a target=xrefwindow id=d62140e3913 href="http://www.ncbi.nlm.nih.gov/pubmed/26861249">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3916 href="http://dx.doi.org/10.1158/1535-7163.MCT-15-0733-T">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726136490">F1000 Recommendation</a></span></li><li><a name=ref-94 class=n-a></a><span class=label>94. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726209854"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3929 class=n-a></a>Wang S, Blois A, El Rayes T, <i> et al.</i>: Development of a prosaposin-derived therapeutic cyclic peptide that targets ovarian cancer via the tumor microenvironment. <i>Sci Transl Med.</i> 2016; <b>8</b>(329): 329ra34. <a target=xrefwindow id=d62140e3940 href="http://www.ncbi.nlm.nih.gov/pubmed/26962158">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3943 href="http://dx.doi.org/10.1126/scitranslmed.aad5653">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726209854">F1000 Recommendation</a></span></li><li><a name=ref-95 class=n-a></a><span class=label>95. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/725773204"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e3956 class=n-a></a>Le Tourneau C, Delord JP, Gonçalves A, <i> et al.</i>: Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. <i>Lancet Oncol.</i> 2015; <b>16</b>(13): 1324–34. <a target=xrefwindow id=d62140e3967 href="http://www.ncbi.nlm.nih.gov/pubmed/26342236">PubMed Abstract </a> | <a target=xrefwindow id=d62140e3970 href="http://dx.doi.org/10.1016/S1470-2045(15)00188-6">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/725773204">F1000 Recommendation</a></span></li><li><a name=ref-96 class=n-a></a><span class=label>96. </span>&nbsp;<span class=citation><a name=d62140e3984 class=n-a></a>NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) Trial. 2017. <a target=xrefwindow id=d62140e3986 href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/nci-supported/nci-match">Reference Source</a></span></li><li><a name=ref-97 class=n-a></a><span class=label>97. </span>&nbsp;<span class=citation><a name=d62140e3995 class=n-a></a>Tse BW, Collins A, Oehler MK, <i> et al.</i>: Antibody-based immunotherapy for ovarian cancer: where are we at? <i>Ann Oncol.</i> 2014; <b>25</b>(2): 322–31. <a target=xrefwindow id=d62140e4006 href="http://www.ncbi.nlm.nih.gov/pubmed/24285017">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4009 href="http://dx.doi.org/10.1093/annonc/mdt405">Publisher Full Text </a></span></li><li><a name=ref-98 class=n-a></a><span class=label>98. </span>&nbsp;<span class=citation><a name=d62140e4018 class=n-a></a>Chester C, Dorigo O, Berek JS, <i> et al.</i>: Immunotherapeutic approaches to ovarian cancer treatment. <i>J Immunother Cancer.</i> 2015; <b>3</b>: 7. <a target=xrefwindow id=d62140e4029 href="http://www.ncbi.nlm.nih.gov/pubmed/25806106">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4032 href="http://dx.doi.org/10.1186/s40425-015-0051-7">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4036 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4372273">Free Full Text </a></span></li><li><a name=ref-99 class=n-a></a><span class=label>99. </span>&nbsp;<span class=citation><a name=d62140e4045 class=n-a></a>De Felice F, Marchetti C, Palaia I, <i> et al.</i>: Immunotherapy of Ovarian Cancer: The Role of Checkpoint Inhibitors. <i>J Immunol Res.</i> 2015; <b>2015</b>: 191832. <a target=xrefwindow id=d62140e4056 href="http://www.ncbi.nlm.nih.gov/pubmed/26236750">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4059 href="http://dx.doi.org/10.1155/2015/191832">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4063 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4508475">Free Full Text </a></span></li><li><a name=ref-100 class=n-a></a><span class=label>100. </span>&nbsp;<span class=citation><a name=d62140e4072 class=n-a></a>Varga A, Piha-Paul SA, Ott PA, <i> et al.</i>: Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. ASCO Meeting Abstracts. 2015; <b>33</b>(Suppl_15): 5510. <a target=xrefwindow id=d62140e4080 href="http://meetinglibrary.asco.org/content/147724-156">Reference Source</a></span></li><li><a name=ref-101 class=n-a></a><span class=label>101. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/717976743"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4089 class=n-a></a>Perren TJ, Swart AM, Pfisterer J, <i> et al.</i>: A phase 3 trial of bevacizumab in ovarian cancer. <i>N Engl J Med.</i> 2011; <b>365</b>(26): 2484–96. <a target=xrefwindow id=d62140e4100 href="http://www.ncbi.nlm.nih.gov/pubmed/22204725">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4103 href="http://dx.doi.org/10.1056/NEJMoa1103799">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/717976743">F1000 Recommendation</a></span></li><li><a name=ref-102 class=n-a></a><span class=label>102. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/716997867"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4117 class=n-a></a>Aghajanian C, Blank SV, Goff BA, <i> et al.</i>: OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. <i>J Clin Oncol.</i> 2012; <b>30</b>(17): 2039–45. <a target=xrefwindow id=d62140e4128 href="http://www.ncbi.nlm.nih.gov/pubmed/22529265">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4131 href="http://dx.doi.org/10.1200/JCO.2012.42.0505">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4135 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3646321">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/716997867">F1000 Recommendation</a></span></li><li><a name=ref-103 class=n-a></a><span class=label>103. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718312260"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4148 class=n-a></a>Pujade-Lauraine E, Hilpert F, Weber B, <i> et al.</i>: Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. <i>J Clin Oncol.</i> 2014; <b>32</b>(13): 1302–8. <a target=xrefwindow id=d62140e4159 href="http://www.ncbi.nlm.nih.gov/pubmed/24637997">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4162 href="http://dx.doi.org/10.1200/JCO.2013.51.4489">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718312260">F1000 Recommendation</a></span></li><li><a name=ref-104 class=n-a></a><span class=label>104. </span>&nbsp;<span class=citation><a name=d62140e4175 class=n-a></a>Farley J: A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women With Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum. 2016. <a target=xrefwindow id=d62140e4177 href="https://clinicaltrials.gov/ct2/show/record/NCT02315430?term=NRG-GY001&amp;rank=1">Reference Source</a></span></li><li><a name=ref-105 class=n-a></a><span class=label>105. </span>&nbsp;<span class=citation><a name=d62140e4186 class=n-a></a>Matulonis UA, Berlin S, Ivy P, <i> et al.</i>: Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. <i>J Clin Oncol.</i> 2009; <b>27</b>(33): 5601–6. <a target=xrefwindow id=d62140e4197 href="http://www.ncbi.nlm.nih.gov/pubmed/19826113">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4200 href="http://dx.doi.org/10.1200/JCO.2009.23.2777">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4204 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2792954">Free Full Text </a></span></li><li><a name=ref-106 class=n-a></a><span class=label>106. </span>&nbsp;<span class=citation><a name=d62140e4213 class=n-a></a>Liu J: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 2016. <a target=xrefwindow id=d62140e4215 href="https://clinicaltrials.gov/ct2/show/record/NCT02446600?term=NRG-GY004&amp;rank=1">Reference Source</a></span></li><li><a name=ref-107 class=n-a></a><span class=label>107. </span>&nbsp;<span class=citation><a name=d62140e4224 class=n-a></a>Lee J: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS). 2016. <a target=xrefwindow id=d62140e4226 href="https://clinicaltrials.gov/ct2/show/record/NCT02502266?term=NRG-GY005&amp;rank=1">Reference Source</a></span></li><li><a name=ref-108 class=n-a></a><span class=label>108. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726377012"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4236 class=n-a></a>Monk BJ, Sill MW, Walker JL, <i> et al.</i>: Randomized Phase II Evaluation of Bevacizumab Versus Bevacizumab Plus Fosbretabulin in Recurrent Ovarian, Tubal, or Peritoneal Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study. <i>J Clin Oncol.</i> 2016; <b>34</b>(19): 2279–86. <a target=xrefwindow id=d62140e4247 href="http://www.ncbi.nlm.nih.gov/pubmed/27217446">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4250 href="http://dx.doi.org/10.1200/JCO.2015.65.8153">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4254 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4962710">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726377012">F1000 Recommendation</a></span></li><li><a name=ref-109 class=n-a></a><span class=label>109. </span>&nbsp;<span class=citation><a name=d62140e4267 class=n-a></a>Monk BJ, Poveda A, Vergote I, <i> et al.</i>: Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncol.</i> 2014; <b>15</b>(8): 799–808. <a target=xrefwindow id=d62140e4278 href="http://www.ncbi.nlm.nih.gov/pubmed/24950985">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4281 href="http://dx.doi.org/10.1016/S1470-2045(14)70244-X">Publisher Full Text </a></span></li><li><a name=ref-110 class=n-a></a><span class=label>110. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726665053"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4290 class=n-a></a>Monk BJ, Poveda A, Vergote I, <i> et al.</i>: Final results of a phase 3 study of trebananib plus weekly paclitaxel in recurrent ovarian cancer (TRINOVA-1): Long-term survival, impact of ascites, and progression-free survival-2. <i>Gynecol Oncol.</i> 2016; <b>143</b>(1): 27–34. <a target=xrefwindow id=d62140e4301 href="http://www.ncbi.nlm.nih.gov/pubmed/27546885">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4304 href="http://dx.doi.org/10.1016/j.ygyno.2016.07.112">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726665053">F1000 Recommendation</a></span></li><li><a name=ref-111 class=n-a></a><span class=label>111. </span>&nbsp;<span class=citation><a name=d62140e4317 class=n-a></a>A Phase 3, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer. 2016. <a target=xrefwindow id=d62140e4319 href="https://clinicaltrials.gov/ct2/show/record/NCT01281254">Reference Source</a></span></li><li><a name=ref-112 class=n-a></a><span class=label>112. </span>&nbsp;<span class=citation><a name=d62140e4328 class=n-a></a>TRINOVA-3: A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers. 2016. <a target=xrefwindow id=d62140e4330 href="https://clinicaltrials.gov/ct2/show/record/NCT01493505?term=trinova-3&amp;rank=1">Reference Source</a></span></li><li><a name=ref-113 class=n-a></a><span class=label>113. </span>&nbsp;<span class=citation><a name=d62140e4339 class=n-a></a>Kaufman B, Shapira-Frommer R, Schmutzler RK, <i> et al.</i>: Olaparib monotherapy in patients with advanced cancer and a germline <i>BRCA1/2</i> mutation. <i>J Clin Oncol.</i> 2015; <b>33</b>(3): 244–50. <a target=xrefwindow id=d62140e4353 href="http://www.ncbi.nlm.nih.gov/pubmed/25366685">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4357 href="http://dx.doi.org/10.1200/JCO.2014.56.2728">Publisher Full Text </a></span></li><li><a name=ref-114 class=n-a></a><span class=label>114. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/718142792"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4367 class=n-a></a>Ledermann J, Harter P, Gourley C, <i> et al.</i>: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. <i>N Engl J Med.</i> 2012; <b>366</b>(15): 1382–92. <a target=xrefwindow id=d62140e4378 href="http://www.ncbi.nlm.nih.gov/pubmed/22452356">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4381 href="http://dx.doi.org/10.1056/NEJMoa1105535">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/718142792">F1000 Recommendation</a></span></li><li><a name=ref-115 class=n-a></a><span class=label>115. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726731816"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4394 class=n-a></a>Ledermann JA, Harter P, Gourley C, <i> et al.</i>: Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. <i>Lancet Oncol.</i> 2016; <b>17</b>(11): 1579–89. <a target=xrefwindow id=d62140e4405 href="http://www.ncbi.nlm.nih.gov/pubmed/27617661">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4408 href="http://dx.doi.org/10.1016/S1470-2045(16)30376-X">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726731816">F1000 Recommendation</a></span></li><li><a name=ref-116 class=n-a></a><span class=label>116. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726825232"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d62140e4421 class=n-a></a>Mirza MR, Monk BJ, Herrstedt J, <i> et al.</i>: Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. <i>N Engl J Med.</i> 2016; <b>375</b>(22): 2154–2164. <a target=xrefwindow id=d62140e4432 href="http://www.ncbi.nlm.nih.gov/pubmed/27717299">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4435 href="http://dx.doi.org/10.1056/NEJMoa1611310">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726825232">F1000 Recommendation</a></span></li><li><a name=ref-117 class=n-a></a><span class=label>117. </span>&nbsp;<span class=citation><a name=d62140e4448 class=n-a></a>Clark R, Zaharoff B: A Study of Niraparib in Patients With Ovarian Cancer Who Have Received Three or Four Previous Chemotherapy Regimens (QUADRA). 2016. <a target=xrefwindow id=d62140e4450 href="https://clinicaltrials.gov/ct2/show/record/NCT02354586?term=niraparib+and+ovarian+cancer&amp;rank=5">Reference Source</a></span></li><li><a name=ref-118 class=n-a></a><span class=label>118. </span>&nbsp;<span class=citation><a name=d62140e4459 class=n-a></a>Bell-McGuinn KM SPS: A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP inhibitor) in Subjects with Previously Untreated Stages III or IV High-Grade Serous Epitheli Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. <a target=xrefwindow id=d62140e4461 href="https://clinicaltrials.gov/ct2/show/record/NCT02470585?term=Phase+3+Placebo-Controlled+Study+of+Carboplatin%2FPaclitaxel+With+or+Without+Concurrent+and+Continuation+Maintenance+Veliparib%3A&amp;rank=1">Reference Source</a></span></li><li><a name=ref-119 class=n-a></a><span class=label>119. </span>&nbsp;<span class=citation><a name=d62140e4470 class=n-a></a>A Phase 2, Open-Label Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2). 2016. <a target=xrefwindow id=d62140e4472 href="https://clinicaltrials.gov/ct2/show/record/NCT01891344?term=ARIEL&amp;rank=1">Reference Source</a></span></li><li><a name=ref-120 class=n-a></a><span class=label>120. </span>&nbsp;<span class=citation><a name=d62140e4482 class=n-a></a>Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3). 2016. <a target=xrefwindow id=d62140e4484 href="https://clinicaltrials.gov/ct2/show/record/NCT01968213?term=ARIEL&amp;rank=2">Reference Source</a></span></li><li><a name=ref-121 class=n-a></a><span class=label>121. </span>&nbsp;<span class=citation><a name=d62140e4493 class=n-a></a>ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients. 2016. <a target=xrefwindow id=d62140e4495 href="https://clinicaltrials.gov/ct2/show/record/NCT02855944?term=ARIEL&amp;rank=3">Reference Source</a></span></li><li><a name=ref-122 class=n-a></a><span class=label>122. </span>&nbsp;<span class=citation><a name=d62140e4504 class=n-a></a>Richardson DL: A Randomized Phase IIB Evaluation of Weekly Paclitaxel plus Pazopanib versus Weekly Paclitaxel plus Placebo in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma. 2016. <a target=xrefwindow id=d62140e4506 href="https://clinicaltrials.gov/ct2/show/record/NCT01468909?term=A+Randomized+Phase+IIB+Evaluation+of+Weekly+Paclitaxel+plus+Pazopanib&amp;rank=1">Reference Source</a></span></li><li><a name=ref-123 class=n-a></a><span class=label>123. </span>&nbsp;<span class=citation><a name=d62140e4515 class=n-a></a>Matulonis UA: A Randomized Phase II Study of NCI Supplied Cabozantinib versus weekly paclitaxel in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. <a target=xrefwindow id=d62140e4517 href="https://clinicaltrials.gov/ct2/show/record/NCT01716715?term=A+Randomized+Phase+II+Study+of+NCI+Supplied+Cabozantinib++versus+weekly+paclitaxel&amp;rank=1">Reference Source</a></span></li><li><a name=ref-124 class=n-a></a><span class=label>124. </span>&nbsp;<span class=citation><a name=d62140e4526 class=n-a></a>Alvarez RD, Sill MW, Davidson SA, <i> et al.</i>: A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a gynecologic oncology group study. <i>Gynecol Oncol.</i> 2014; <b>133</b>(3): 433–8. <a target=xrefwindow id=d62140e4537 href="http://www.ncbi.nlm.nih.gov/pubmed/24708919">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4540 href="http://dx.doi.org/10.1016/j.ygyno.2014.03.571">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4544 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4057915">Free Full Text </a></span></li><li><a name=ref-125 class=n-a></a><span class=label>125. </span>&nbsp;<span class=citation><a name=d62140e4553 class=n-a></a>Burger R: Phase II Randomized Trial of Nivolumab With or Without Ipilimumab in Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer. 2016. <a target=xrefwindow id=d62140e4555 href="https://clinicaltrials.gov/ct2/show/record/NCT02498600?term=nivolumab+and+ovarian+cancer&amp;rank=5">Reference Source</a></span></li><li><a name=ref-126 class=n-a></a><span class=label>126. </span>&nbsp;<span class=citation><a name=d62140e4565 class=n-a></a>Burger R: A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer. 2016. <a target=xrefwindow id=d62140e4567 href="https://clinicaltrials.gov/ct2/show/record/NCT02713386?term=Ruxolitinib+and+ovarian+cancer&amp;rank=1">Reference Source</a></span></li><li><a name=ref-127 class=n-a></a><span class=label>127. </span>&nbsp;<span class=citation><a name=d62140e4576 class=n-a></a>Monk BJ: Randomized Phase II Study of VTX-2337 in combination with pegylated liposomal doxorubicin (PLD) vs. PLD alone in the treatment of recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer. 2016. <a target=xrefwindow id=d62140e4578 href="https://clinicaltrials.gov/ct2/show/record/NCT01666444?term=VTX-2337+and+ovarian+cancer&amp;rank=2">Reference Source</a></span></li><li><a name=ref-128 class=n-a></a><span class=label>128. </span>&nbsp;<span class=citation><a name=d62140e4587 class=n-a></a>Behbakht K, Sill MW, Darcy KM, <i> et al.</i>: Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. <i>Gynecol Oncol.</i> 2011; <b>123</b>(1): 19–26. <a target=xrefwindow id=d62140e4598 href="http://www.ncbi.nlm.nih.gov/pubmed/21752435">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4601 href="http://dx.doi.org/10.1016/j.ygyno.2011.06.022">Publisher Full Text </a> | <a target=xrefwindow id=d62140e4605 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3336961">Free Full Text </a></span></li><li><a name=ref-129 class=n-a></a><span class=label>129. </span>&nbsp;<span class=citation><a name=d62140e4614 class=n-a></a>Matulonis UA, Harter P, Gourley C, <i> et al.</i>: Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a <i>BRCA</i> mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. <i>Cancer.</i> 2016; <b>122</b>(12): 1844–52. <a target=xrefwindow id=d62140e4628 href="http://www.ncbi.nlm.nih.gov/pubmed/27062051">PubMed Abstract </a> | <a target=xrefwindow id=d62140e4632 href="http://dx.doi.org/10.1002/cncr.29995">Publisher Full Text </a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jan 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-84/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-84/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Washington University School of Medicine, St. Louis, MO, USA<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-84/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 27 Jan 2017, 6:84 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.9977.1">https://doi.org/10.12688/f1000research.9977.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Mills K and Fuh K. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=10752 data-id=9977 data-downloads="" data-views="" data-scholar="10.12688/f1000research.9977.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-84/v1/pdf?article_uuid=ff0c7cca-6654-4c5f-9f28-37d70e478d29" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.9977.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Mills K and Fuh K. Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):84 (<a href="https://doi.org/10.12688/f1000research.9977.1" target=_blank>https://doi.org/10.12688/f1000research.9977.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=9977 id=mobile-track-article-signin-9977 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/9977?target=/articles/6-84/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=10752 /> <input name=articleId type=hidden value=9977 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Steven Narod</strong>, Women's College Research Institute, Women's College Hospital, Canada; Dalla Lana School of Public Health, University of Toronto, Canada </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Jonathan Berek</strong>, Stanford Women's Cancer Center and Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Ronny Drapkin</strong>, Penn Ovarian Cancer Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania, Perelman School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 27 Jan 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-84/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-84/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19780-19410></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=2272-19409></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19779-19408></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-84/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>27 Jan 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Steven Narod</strong>, Women's College Research Institute, Women's College Hospital, Canada; Dalla Lana School of Public Health, University of Toronto, Canada </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Jonathan Berek</strong>, Stanford Women's Cancer Center and Stanford Comprehensive Cancer Institute, Stanford University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Ronny Drapkin</strong>, Penn Ovarian Cancer Research Center, Department of Obstetrics & Gynecology, University of Pennsylvania, Perelman School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-84/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-84/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent Advances in Understanding, Diagnosing,...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-84/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-84/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-84/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Mills K and Fuh K');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-84/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-84",
            templates : {
                twitter : "Recent Advances in Understanding, Diagnosing, and Treating Ovarian.... Mills K and Fuh K, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-84/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/9977/10752")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "10752");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "19408": 0,
                           "19409": 0,
                           "19410": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "9cf4f048-851d-42ab-ad88-2e8f34a1d578";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-84.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-84.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-84.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-84.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-84.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>